<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83737</article-id><article-id pub-id-type="doi">10.7554/eLife.83737</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Selective loss of CD107a TIGIT+ memory HIV-1-specific CD8+ T cells in PLWH over a decade of ART</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-295048"><name><surname>Blanch-Lombarte</surname><given-names>Oscar</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8317-7535</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-295049"><name><surname>Ouchi</surname><given-names>Dan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-295050"><name><surname>Jimenez-Moyano</surname><given-names>Esther</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294667"><name><surname>Carabelli</surname><given-names>Julieta</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294668"><name><surname>Marin</surname><given-names>Miguel Angel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5294-6007</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294669"><name><surname>Peña</surname><given-names>Ruth</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294670"><name><surname>Pelletier</surname><given-names>Adam</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294671"><name><surname>Talla</surname><given-names>Aarthi</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294672"><name><surname>Sharma</surname><given-names>Ashish</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-6362"><name><surname>Dalmau</surname><given-names>Judith</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294673"><name><surname>Santos</surname><given-names>José Ramón</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-235618"><name><surname>Sékaly</surname><given-names>Rafick-Pierre</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294674"><name><surname>Clotet</surname><given-names>Bonaventura</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-43905"><name><surname>Prado</surname><given-names>Julia G</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5439-4645</contrib-id><email>jgarciaprado@irsicaixa.es</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>IrsiCaixa AIDS Research Institute</institution><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052g8jq94</institution-id><institution>Universitat Autònoma de Barcelona, Cerdanyola del Vallès</institution></institution-wrap><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/051fd9666</institution-id><institution>Pathology Department, Case Western Reserve University</institution></institution-wrap><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wxdxa47</institution-id><institution>Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol</institution></institution-wrap><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wxdxa47</institution-id><institution>Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol</institution></institution-wrap><addr-line><named-content content-type="city">Badalona</named-content></addr-line><country>Spain</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03bzdww12</institution-id><institution>Germans Trias i Pujol Research Institute (IGTP)</institution></institution-wrap><addr-line><named-content content-type="city">Badalona</named-content></addr-line><country>Spain</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/006zjws59</institution-id><institution>Faculty of Medicine, University of Vic - Central University of Catalonia (UVic-UCC)</institution></institution-wrap><addr-line><named-content content-type="city">Catalonia</named-content></addr-line><country>Spain</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00ca2c886</institution-id><institution>CIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kirchhoff</surname><given-names>Frank</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032000t02</institution-id><institution>Ulm University Medical Center</institution></institution-wrap><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Choi</surname><given-names>Murim</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04h9pn542</institution-id><institution>Seoul National University</institution></institution-wrap><country>Republic of Korea</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>19</day><month>09</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83737</elocation-id><history><date date-type="received" iso-8601-date="2022-09-27"><day>27</day><month>09</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-08-30"><day>30</day><month>08</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-07-14"><day>14</day><month>07</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.07.13.499924"/></event></pub-history><permissions><copyright-statement>© 2023, Blanch-Lombarte et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Blanch-Lombarte et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83737-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-83737-figures-v1.pdf"/><abstract><p>The co-expression of inhibitory receptors (IRs) is a hallmark of CD8+ T-cell exhaustion (Tex) in people living with HIV-1 (PLWH). Understanding alterations of IRs expression in PLWH on long-term antiretroviral treatment (ART) remains elusive but is critical to overcoming CD8+ Tex and designing novel HIV-1 cure immunotherapies. To address this, we combine high-dimensional supervised and unsupervised analysis of IRs concomitant with functional markers across the CD8+ T-cell landscape on 24 PLWH over a decade on ART. We define irreversible alterations of IRs co-expression patterns in CD8+ T cells not mitigated by ART and identify negative associations between the frequency of TIGIT+ and TIGIT+ TIM-3+ and CD4+ T-cell levels. Moreover, changes in total, SEB-activated, and HIV-1-specific CD8+ T cells delineate a complex reshaping of memory and effector-like cellular clusters on ART. Indeed, we identify a selective reduction of HIV-1 specific-CD8+ T-cell memory-like clusters sharing TIGIT expression and low CD107a that can be recovered by mAb TIGIT blockade independently of IFNγ and IL-2. Collectively, these data characterize with unprecedented detail the patterns of IRs expression and functions across the CD8+ T-cell landscape and indicate the potential of TIGIT as a target for Tex precision immunotherapies in PLWH at all ART stages.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>inhibitory receptors</kwd><kwd>HIV-1-specific CD8+ T cells</kwd><kwd>TIGIT</kwd><kwd>CD107a</kwd><kwd>single-cell CD8+ dynamics</kwd><kwd>people living with HIV-1</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004587</institution-id><institution>Institute of Health Carlos III</institution></institution-wrap></funding-source><award-id>PI17/00164</award-id><principal-award-recipient><name><surname>Prado</surname><given-names>Julia G</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100004895</institution-id><institution>Catalan Government and the European Social Fund</institution></institution-wrap></funding-source><award-id>AGAUR-FI_B 00582 PhD fellowship</award-id><principal-award-recipient><name><surname>Blanch-Lombarte</surname><given-names>Oscar</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Redes Temáticas de Investigación en SIDA</institution></institution-wrap></funding-source><award-id>ISCIII RETIC RD16/0025/0041</award-id><principal-award-recipient><name><surname>Jimenez-Moyano</surname><given-names>Esther</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100016387</institution-id><institution>Grifols</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Prado</surname><given-names>Julia G</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>PLWH over a decade of ART showed a significant reshaping of the function and expression of inhibitory receptors across the CD8+ T cell landscape, ultimately leading to a decrease of CD107a TIGIT HIV-1-specific CD8+ T cells recovered by TIGIT blockade.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The ART introduction has been the most successful strategy to control viral replication, transforming HIV-1 into a chronic condition. However, ART does not cure the infection, and treatment is required lifelong due to a stable viral reservoir, raising the need to find a cure for people living with HIV-1 (PLWH). A sterilizing or functional cure aims to eliminate or control HIV-1 in the absence of ART. In both scenarios, HIV-1-specific CD8+ T-cells are likely to play an essential role as they have been widely recognized as a critical factor in the natural control of viral replication (<xref ref-type="bibr" rid="bib10">Borrow et al., 1994</xref>; <xref ref-type="bibr" rid="bib20">Collins et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">McBrien et al., 2018</xref>; <xref ref-type="bibr" rid="bib13">Cartwright et al., 2016</xref>; <xref ref-type="bibr" rid="bib28">Goulder and Walker, 2012</xref>). Proliferative capacity, polyfunctionality, and ex vivo antiviral potency are features of HIV-1-specific CD8+T cells associated with spontaneous viral control (<xref ref-type="bibr" rid="bib54">Sáez-Cirión et al., 2007</xref>; <xref ref-type="bibr" rid="bib42">Migueles et al., 2008</xref>; <xref ref-type="bibr" rid="bib43">Nguyen et al., 2019</xref>; <xref ref-type="bibr" rid="bib46">Perdomo-Celis et al., 2019a</xref>).</p><p>Although ART in PLWH normalizes the levels of CD8+ T-cells and potentially preserves their functional characteristics (<xref ref-type="bibr" rid="bib46">Perdomo-Celis et al., 2019a</xref>; <xref ref-type="bibr" rid="bib47">Perdomo-Celis et al., 2019b</xref>; <xref ref-type="bibr" rid="bib62">Tavenier et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Serrano-Villar et al., 2014</xref>), microbial translocation and continuous immune activation lead to long-term CD8+ T-cell dysfunction and exhaustion (Tex), a critical barrier for HIV-1 curative interventions (<xref ref-type="bibr" rid="bib51">Ruiz et al., 2018</xref>; <xref ref-type="bibr" rid="bib34">Jiang et al., 2020</xref>; <xref ref-type="bibr" rid="bib33">Hoffmann et al., 2016</xref>). CD8+ Tex is defined by the persistent co-expression of inhibitory receptors (IRs) and the progressive loss of immune effector functions linked to transcriptional, epigenetic and metabolic changes (<xref ref-type="bibr" rid="bib57">Sekine et al., 2020</xref>; <xref ref-type="bibr" rid="bib12">Buggert et al., 2014</xref>; <xref ref-type="bibr" rid="bib7">Bengsch et al., 2016</xref>; <xref ref-type="bibr" rid="bib58">Sen et al., 2016</xref>). In HIV-1 infection, IRs are continuously expressed despite long-term suppressive ART (<xref ref-type="bibr" rid="bib11">Breton et al., 2013</xref>; <xref ref-type="bibr" rid="bib73">Yamamoto et al., 2011</xref>; <xref ref-type="bibr" rid="bib19">Cockerham et al., 2014</xref>; <xref ref-type="bibr" rid="bib52">Rutishauser et al., 2017</xref>; <xref ref-type="bibr" rid="bib61">Tauriainen et al., 2017</xref>; <xref ref-type="bibr" rid="bib16">Chew et al., 2016</xref>; <xref ref-type="bibr" rid="bib65">Trautmann et al., 2006</xref>) and have been associated with disease progression and immune status in PLWH (<xref ref-type="bibr" rid="bib16">Chew et al., 2016</xref>; <xref ref-type="bibr" rid="bib21">Day et al., 2006</xref>; <xref ref-type="bibr" rid="bib29">Graydon et al., 2019</xref>; <xref ref-type="bibr" rid="bib31">Gupta et al., 2015</xref>; <xref ref-type="bibr" rid="bib36">Jones et al., 2008</xref>; <xref ref-type="bibr" rid="bib63">Teigler et al., 2017</xref>; <xref ref-type="bibr" rid="bib64">Tian et al., 2015</xref>). Thus, the expression of IRs is linked to diminished functionality and is a hallmark of CD8+ Tex in PLWH.</p><p>The interest in evaluating the blocking of IRs or immune checkpoint blockade (ICB) in PLWH as a therapeutic strategy to reverse CD8+ Tex increases (<xref ref-type="bibr" rid="bib65">Trautmann et al., 2006</xref>; <xref ref-type="bibr" rid="bib21">Day et al., 2006</xref>). Over the last years, several studies supported the recovery of proliferative capacity, cell survival, and cytokine production of HIV-1-specific CD8+ T-cells through ICB (<xref ref-type="bibr" rid="bib15">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib9">Blanch-Lombarte et al., 2019</xref>). The blockade of the PD-1/PDL-1 axis has been extensively studied, demonstrating the functional recovery of HIV-1-specific CD8+ T-cells in PLWH (<xref ref-type="bibr" rid="bib65">Trautmann et al., 2006</xref>; <xref ref-type="bibr" rid="bib21">Day et al., 2006</xref>). Moreover, alternative pathways to PD-1 /PDL-1, including LAG-3, TIGIT, and TIM-3, have been explored as candidates for ICB therapies for HIV-1 infection (<xref ref-type="bibr" rid="bib15">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Sakuishi et al., 2010</xref>; <xref ref-type="bibr" rid="bib32">Harjunpää and Guillerey, 2020</xref>; <xref ref-type="bibr" rid="bib40">Maruhashi et al., 2020</xref>). Also, recent data support the combinatorial use of ICB to favour synergistic effects on the recovery of HIV-1-specific CD4+ and CD8+ T-cell function (<xref ref-type="bibr" rid="bib5">Attanasio and Wherry, 2017</xref>; <xref ref-type="bibr" rid="bib17">Chiu et al., 2022</xref>).</p><p>The unprecedented success of the clinical use of ICB in the cancer field (<xref ref-type="bibr" rid="bib68">Vaddepally et al., 2020</xref>; <xref ref-type="bibr" rid="bib66">Twomey and Zhang, 2021</xref>) has prompted the clinical evaluation of ICB in PLWH (<xref ref-type="bibr" rid="bib27">Gonzalez-Cao et al., 2020</xref>) to boost immunity to reduce or eliminate the viral reservoir. However, clinical evidence on the impact of ICB as an HIV-1 cure intervention continues to be controversial (<xref ref-type="bibr" rid="bib9">Blanch-Lombarte et al., 2019</xref>; <xref ref-type="bibr" rid="bib24">Fromentin et al., 2019</xref>; <xref ref-type="bibr" rid="bib39">Le Garff et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Gay et al., 2017</xref>; <xref ref-type="bibr" rid="bib30">Guihot et al., 2018</xref>; <xref ref-type="bibr" rid="bib67">Uldrick et al., 2022</xref>). In this context, the simultaneous characterization of IRs co-expression and functional patterns across CD8+ T-cells is critical to understanding Tex regulation in PLWH. This information is essential to identify novel targets for precise immunotherapies in PLWH on ART (<xref ref-type="bibr" rid="bib22">Deeks et al., 2021</xref>).</p><p>To address these questions, we performed supervised and unsupervised immunophenotypic analyses of IRs (PD-1, TIGIT, LAG-3, TIM-3, CD39), and functional markers (CD107a, IFNγ, and IL-2) across the landscape of CD8+ T-cells over a decade of ART in PLWH and compared to PLWH with early infection and healthy individuals. We profile changes of bulk, SEB-activated, and HIV-1-specific CD8+ T-cells in PLHW and unfold a selective decrease of memory-like HIV-1-specific CD8+ clusters sharing TIGIT expression and low CD107a in PLWH on ART. Moreover, TIGIT blockade rescues CD107a expression without changes in IFNγ or IL-2 production on HIV-1-specific CD8+ T-cells. Of note, the response to TIGIT, TIM-3, or TIGIT + TIM-3 blockade was heterogeneous across HIV-1-specific CD8+ T-cell differentiation stages and functions, indicating the plasticity and complexity of the IRs pathways as targets for immune-base cure interventions.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Alterations in CD8+ T-cell IRs frequencies and expression patterns in PLWH are not mitigated by ART</title><p>Although the co-expression of IRs is a hallmark of CD8+ Tex in HIV-1 infection (<xref ref-type="bibr" rid="bib11">Breton et al., 2013</xref>; <xref ref-type="bibr" rid="bib73">Yamamoto et al., 2011</xref>; <xref ref-type="bibr" rid="bib19">Cockerham et al., 2014</xref>; <xref ref-type="bibr" rid="bib52">Rutishauser et al., 2017</xref>; <xref ref-type="bibr" rid="bib61">Tauriainen et al., 2017</xref>; <xref ref-type="bibr" rid="bib16">Chew et al., 2016</xref>; <xref ref-type="bibr" rid="bib65">Trautmann et al., 2006</xref>), a detailed characterization of the combinatorial expression of IRs across CD8+ T-cell lineages in PLWH on long-term ART is still missing. To do this, we combined the analyses of IRs (PD-1, TIGIT, LAG-3, TIM-3, and CD39) and lineage markers (CD45RA, CCR7, and CD27) in CD8+ T-cells from longitudinal samples in PLWH on ART by flow-cytometry (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). We compare three groups; healthy controls (HC), PLWH with early infection (Ei), and PLWH on ART (S) with longitudinal samples available a median period of 2.2 (S1) and 10.1 (S2) years on fully suppressive ART (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). The epidemiological and clinical characteristics of the study groups are detailed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Patterns of IRs co-expression and correlations with CD4+ T-cell counts in PLWH.</title><p>(<bold>A</bold>) Overview of study design and study groups, healthy controls (HC), PLWH in early HIV-1 infection (Ei), and PLWH on fully suppressive ART (S) in S1 and S2 time points. (<bold>B</bold>) The expression of IRs summarized in the pie chart is none, one, two, or more than three IRs expressed in CD8+ T-cell subsets. For statistical analysis, we used permutation tests using SPICE software. (<bold>C</bold>) Scatter plots showing the median and interquartile ranges of IR combinations in CD8+ T- cell subsets. (<bold>D</bold>) Scatter plots of the frequencies of single TIGIT<sup>+</sup> expression in CM and TIGIT<sup>+</sup>TIM-3<sup>+</sup> expression in EM and effector EFF CD8+ T cells. (<bold>E–G</bold>) Correlations between CD4+ T-cell counts as a function of TIGIT<sup>+</sup>, TIGIT<sup>+</sup>TIM-3<sup>+</sup>, and combinations of IRs from total CD8+ T-cells and subsets in Ei (<bold>E</bold>), S1 (<bold>F</bold>), and S2 (<bold>G</bold>). The data in B to D represent the mean of two technical replicates. We used the Mann-Whitney U test for intergroup comparison (HC, Ei, S1, and S2) and the signed-rank test for intragroup comparison (S1 and S2). Holm’s method was used to adjust statistical tests for multiple comparisons. All possible correlations of the 32 Boolean IRs combinations are not shown. p-values: *&lt;0.05, **&lt;0.005 and ***&lt;0.0005. Sample sizes in <bold>A</bold>: HC (24), Ei (24), S1(24), S2 (24). Sample sizes in <bold>B–G</bold>: HC (20), Ei (21), S1(18), S2 (21).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Epidemiological and clinical data of study groups; healthy controls (HC), PLWH in early infection (Ei), and PLWH on fully suppressive ART (<bold>S</bold>) in S1 and S2 time points.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83737-fig1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Frequencies of IRs expression shown in pie charts as 0 to &gt;3 IRs expressed in CD8+ T-cell subsets and study groups.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83737-fig1-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>Frequencies of the 32 possible combinations of expressions for TIGIT, PD-1, LAG-3, TIM-3, and CD39 in CD8+ T-cell subsets per study group.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83737-fig1-data3-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata4"><label>Figure 1—source data 4.</label><caption><title>Frequencies of IRs expression in total and CD8+ T-cell subsets per study group.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83737-fig1-data4-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata5"><label>Figure 1—source data 5.</label><caption><title>Correlations between CD4+ T-cell counts and TIGIT<sup>+</sup>, TIGIT<sup>+</sup>TIM-3<sup>+</sup>, and combinations of IRs in total and CD8+ T-cell subsets per study group.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83737-fig1-data5-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83737-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Gating strategy for identifying total CD8+ T-cell subsets and IRs expression levels.</title><p>(<bold>A</bold>) Zebra dot plots showing the gating strategy used for the identification of total CD8+ and cellular using lineage markers (CD45RA, CCR7, and CD27) subsets as follow; naive (CD45RA+ CCR7+ CD27+), Eff (CD45RA+ CCR7- CD27-), CM (CD45RA- CCR7+ CD27+), TM (CD45RA- CCR7- CD27+), and EM (CD45RA-, CCR7-, and CD27-). (<bold>B</bold>) Zebra dot plots of FMO and IRs staining demonstrating TIGIT, PD-1, LAG-3, TIM-3, and CD39 expression in cryopreserved PBMCs. Sample sizes: HC (20), Ei (21), S1(18), S2 (21).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83737-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Expression profile of IRs in total and CD8+ T-cell subsets across study groups.</title><p>(<bold>A</bold>) Frequency of CD8+ T-cells and IRs expression in total CD8+ T cells across study groups (HC, Ei, <bold>S1 and S2</bold>) (<bold>B</bold>) Frequency of IRs expression in CD8+ T-cell subsets. Scatter plots represent median and interquartile ranges. (<bold>C</bold>) Co-expression profile of IRs across CD8+ T-cell subset. Pie charts represent the frequency for the 32 possible combinations for TIGIT, PD-1, LAG-3, TIM-3, and CD39 expression. The pie charts represent the frequency of expression according to the color code, and the arcs indicate the frequency of each IR. We used permutation tests of SPICE software for statistical analysis of IRs co-expression data. We used the Mann-Whitney U test for intergroup analyses and the signed-rank test for intragroup analyses. Holm’s method was used to adjust statistical tests for multiple comparisons. p-values: *&lt;0.05, **&lt;0.005, ***&lt;0.0005, ****&lt;0.00001. Sample sizes: HC (20), Ei (21), S1(18), S2 (21).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83737-fig1-figsupp2-v1.tif"/></fig></fig-group><p>As shown in <xref ref-type="fig" rid="fig1">Figure 1</xref> (<xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>), we found persistent alterations in the expression and co-expression of IRs in naïve, central memory (CM), and transitional memory (TM) CD8+ T-cells in PLWH on ART. These perturbations were maintained despite prolonged ART (S2) in naive and CM, but not TM cells compared to HC. Deconvolution of IRs co-expression patterns by the number of receptors expressed (0, 1, 2, &gt;3) further delineates a significant reduction of Naïve, CM, and TM CD8+ T-cells lacking IRs expression concomitant with a significant increase of CD8+ T-cells expressing one (Naïve and CM) or &gt;3 IRs (TM) on ART (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Moreover, we observed an augment in effector memory (EM), TM, and effector (EFF) CD8+ T-cells co-expressing &gt;3 IRs in Ei and S1 that normalized in S2 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Of note, out of the 32 possible combinations of IRs expression studied in CD8+ T-cell subsets (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>, <xref ref-type="supplementary-material" rid="fig1sdata3">Figure 1—source data 3</xref>), single TIGIT<sup>+</sup> expression in CM and dual TIGIT<sup>+</sup>TIM-3<sup>+</sup> co-expression in EFF CD8+ T-cells accounted for continuous increases in frequency under suppressive ART (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, <xref ref-type="supplementary-material" rid="fig1sdata3">Figure 1—source data 3</xref>). We confirmed similar increases in the frequency of TIGIT in total, CM, and TM CD8+ T-cells on ART. These data contrast with transient changes in other IRs upon infection normalizing with ART (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>, <xref ref-type="supplementary-material" rid="fig1sdata4">Figure 1—source data 4</xref>).</p><p>These initial findings led us to postulate associations between the expression of IRs in CD8+ T-cells, persistent immune activation, and the degree of CD4+ T-cell immune recovery in PLWH on ART. For this purpose, we performed correlation analyses that revealed several negative associations between the frequency of CD8+ T-cells expressing IRs and CD4+ T-cell counts across study groups (<xref ref-type="fig" rid="fig1">Figure 1E–G</xref>, <xref ref-type="supplementary-material" rid="fig1sdata5">Figure 1—source data 5</xref>). Focusing on S1 (<xref ref-type="fig" rid="fig1">Figure 1F</xref>), we found significant negative correlations between CD4+ T-cell counts and frequencies of CM CD8+ T-cells expressing 2 (p=0.0054, <italic>r</italic>=−0.64) and &gt;1 IRs (p=0.0087, <italic>r</italic>=−0.61). Focusing on S2 (<xref ref-type="fig" rid="fig1">Figure 1G</xref>), we observed significant negative correlations between CD4+ T-cell counts and the frequency of total CD8+ T cells expressing TIGIT<sup>+</sup> (p=0.0157, <italic>r</italic>=−0.58), expressing 1 IRs (p=0.0386, <italic>r</italic>=−0.54) or &gt;1 IRs (p=0.0386, <italic>r</italic>=−0.51). At the level of CD8+ T-cell subsets, the expression of 2 IRs in CM and &gt;1 IR in TM negatively correlated with CD4+ T-cell counts (p=0.0072, <italic>r</italic>=−0.64; p=0.0346, <italic>r</italic>=−0.52, respectively; <xref ref-type="fig" rid="fig1">Figure 1G</xref>). These correlations further indicate a negative relationship between IRs expression patterns and immune status in PLWH on long-term suppressive ART.</p><p>In summary, these data support changes in IRs expression not mitigated by long-term ART in total and CD8+ T-cell subsets expressing one or &gt;1 IRs, particularly TIGIT<sup>+</sup> and TIGIT<sup>+</sup>TIM-3<sup>+</sup>. These findings also uncover negative associations between IRs expression in CD8+ T-cells and CD4+ T-cell levels in PLWH on ART.</p></sec><sec id="s2-2"><title>Unsupervised phenotypic analyses of IRs across the CD8+ T-cell landscape in PLWH on ART</title><p>Next, to further characterize IRs expression across CD8+ T cells in PLWH on ART, we performed an unsupervised net-SNE analysis of flow-cytometry data. We concatenated 1,988,936 total CD8+ T-cells and analyzed the phenotypes with the topographical regions of each surface marker tested (<xref ref-type="fig" rid="fig2">Figure 2A-B</xref>, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). CD8+ T cells were classified into 38 cellular clusters distributed according to the relative marker expression of 14 parameters and represented using net-SNE and heatmaps (<xref ref-type="fig" rid="fig2">Figure 2C-D</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Unsupervised net-SNE analyses of total CD8+ T-cells.</title><p>(<bold>A</bold>) Gating strategy for selecting total CD8+ T-cells (top), net-SNE plots of HC, Ei, S1, S2 and all merge groups. (<bold>B</bold>) Representative net-SNE visualization of surface markers. The colour gradient displays the relative marker expression. (<bold>C</bold>) Unsupervised KNN algorithm of 38 clusters colored according to the legend. Only clusters with statistical differences are represented in the legend. (<bold>D</bold>) Heatmap of the median biexponential-transformed marker expression normalized to a –3–3 range of respective markers. Asterisks represent the clusters with statistical differences. (<bold>E–F</bold>) Scatter plots of intergroup (HC, Ei, S1 and S2) and intragroup (S1 and S2) cluster comparisons. Data represent the median and interquartile ranges of cluster cell frequency. We used the Mann-Whitney U test for intergroup analyses and the signed-rank test for intragroup analyses. Holm’s method was used to adjust statistical tests for multiple comparisons. p-values: *&lt;0.05, **&lt;0.005 and ***&lt;0.0005. Sample sizes for <bold>A–F</bold>: HC (20), Ei (21), S1(18), S2 (21).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Unsupervised net-SNE analyses of total CD8+ T-cells.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83737-fig2-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Cluster cell frequencies from net-SNE analyses in total CD8+ T-cells per study group.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83737-fig2-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83737-fig2-v1.tif"/></fig><p>Out of the 38 clusters identified, we found eight cellular clusters (#1, #2, #6, #7, #9, #10, #11, and #12) with significant differences by inter- and intragroup comparisons (<xref ref-type="fig" rid="fig2">Figure 2D–E</xref>). Most of the differentially expressed clusters shared memory-like phenotypes. Of note, clusters #6, #7, and #12 shared memory-like phenotypes and low expression of IRs. Meanwhile, clusters #9 and #10 shared effector-like phenotypes and co-expression of IRs, including TIGIT, LAG-3, and low TIM-3 (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Briefly, intergroup analyses demonstrated significant changes in composition and frequency with a decrease of #1, #6, and an increase of #10 in Ei compared with HC. Also, clusters #1 and #2 decreased in S1 and S2, respectively, and clusters #9, #10, #11, and #12 increased in S1 while tended to normalize in S2 compared with HC (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>). Intragroup analyses further supported changes in cluster frequency and composition during long-term ART. Meanwhile, clusters #6 and #7 increased, and #9 and #11 decreased over time on ART (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). These data support an expansion of memory-like clusters with low IR expression (#6 and #7) and a contraction of effector-like clusters sharing TIGIT expression (#9 and #11) during ART. Thus, unsupervised analyses support cellular clusters' continuous expansion and contraction in frequency and composition across the landscape of CD8+ T-cells in PLWH on ART.</p></sec><sec id="s2-3"><title>Unsupervised phenotypic characterisation of SEB-activated CD8+ T cells in PLWH on ART</title><p>Then, we evaluate CD8+ T-cell responses by bacterial superantigen activation with Staphylococcal enterotoxin B (SEB). Using SEB can provide complementary information on T-cell activation in response to pathogens involved in the disease by stimulating TCR-VB clonotypes (<xref ref-type="bibr" rid="bib63">Teigler et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Kou et al., 1998</xref>; <xref ref-type="bibr" rid="bib17">Chiu et al., 2022</xref>). In this context, we analysed IRs expression and functional markers using unsupervised net-SNE analysis. We defined SEB-activated CD8+ T cells by the expression of at least one functional marker (CD107a, IFNγ, IL-2) upon incubation with SEB, as previously described (<xref ref-type="bibr" rid="bib25">Gaffen and Liu, 2004</xref>; <xref ref-type="bibr" rid="bib1">Akdis et al., 2016</xref>; <xref ref-type="bibr" rid="bib70">Voskoboinik et al., 2015</xref>; <xref ref-type="bibr" rid="bib2">Aktas et al., 2009</xref>; <xref ref-type="bibr" rid="bib8">Bhat et al., 2017</xref>, <xref ref-type="fig" rid="fig3">Figure 3A,B</xref>, <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>). We concatenated 253,021 SEB-activated CD8+ T-cells and identified 29 unique clusters represented by net-SNE and heatmaps (<xref ref-type="fig" rid="fig3">Figure 3C-D</xref>). Only six of the 29 clusters showed statistical differences by inter- and intragroup comparisons (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). All differential clusters shared memory-like phenotypes (#2, #3, #5, #8, and #14) except cluster #6, with effector-like phenotype and low TIGIT expression. In addition, we observed a functional exclusion of clusters expressing IL-2 (#5 and #6) and those expressing CD107a and IFNγ (#2, #3, and #8; <xref ref-type="fig" rid="fig3">Figure 3D</xref>). Intergroup comparisons identified increases in cluster #2 and a reduction of #14 and #5 with HIV-1 infection compared to HC. Additionally, ART was linked to the decrease of #5, #6, and #14 in S1 and #3 in S2 when compared with HC (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref>). Moreover, intragroup analyses identified an increase in clusters #6 and #14 and a reduction in #3 and #8 on ART. Of note, #6 characterizes by IL-2 expression in the without TIGIT expression. Meanwhile, clusters #3 and #8 express CD107a, IFNγ and variable expression of IRs (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). In agreement with unsupervised clustering analyses, classical supervised analyses identified an augment of CD107a and IFNγ SEB-activated CD8+ T-cells with Ei that normalized over time on ART. Also, we delineate significant increases of IL-2 SEB-activated CD8+ T-cells across subsets and time on ART (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="fig3sdata3">Figure 3—source data 3</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Unsupervised net-SNE analyses of SEB-activated CD8+ T-cells.</title><p>(<bold>A</bold>) Gating representation of CD107a, IFNγ and IL-2 expression in HIV-1-specific CD8+ T-cells (top), net-SNE plots of HC, Ei, S1, S2 and merge groups of SEB-activated CD8+ T-cells (bottom). (<bold>B</bold>) Representative net-SNE visualization of IR expression, lineage, and functional markers. The color gradient displays relative marker expression. (<bold>C</bold>) Unsupervised KNN algorithm for 29 polyclonal clusters color-coded according to the legend. Clusters with statistical differences between groups are represented in the legend. (<bold>D</bold>) Heatmap of the median biexponential-transformed marker expression normalized to a –3–3 range of respective markers. Asterisks represent the clusters with intergroup statistical differences. (<bold>E–F</bold>) Scatter plots of intergroup (HC, Ei, S1 and S2) and intragroup (S1 and S2) cluster comparisons. Data represent the median and interquartile ranges of cluster cell frequency. We used the Mann-Whitney U test for intergroup analyses and the signed-rank test for intragroup analyses. Holm’s method was used to adjust statistical tests for multiple comparisons. p-values: *&lt;0.05, **&lt;0.005, ***&lt;0.0005. Sample sizes: HC (20), Ei (21), S1(18), S2 (21).</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Unsupervised net-SNE analyses of SEB-activated CD8+ T-cells.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83737-fig3-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Cluster cell frequencies from net-SNE analyses of SEB-activated CD8+ T-cells per study group.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83737-fig3-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Supervised analyses of CD107a, IFNγ and IL-2 frequencies of SEB-activated CD8+ T-cells per study groups.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83737-fig3-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83737-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Supervised analyses of SEB-activated CD8+ T-cells.</title><p>(<bold>A</bold>) The total frequency of CD107a, IFNγ and IL-2 SEB-activated CD8+ T-cells in HC, Ei, S1, and S2. Data represent median and interquartile ranges. (<bold>B</bold>) Table of median frequencies of CD107a, IFNγ and IL-2 SEB-activated CD8+ T-cells. (<bold>C</bold>) Frequency of IL-2 SEB-activated CD8+ T-cell subsets in S1 and S2. We used the Mann-Whitney U test for independent median intergroup comparison and the signed-rank test for paired median changes between S1 and S2. The Holm’s method was used to adjust statistical tests for multiple comparisons. p-values: *&lt;0.05, **&lt;0.005, ***&lt;0.0005. Sample sizes: HC (20), Ei (21), S1(18), S2 (21).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83737-fig3-figsupp1-v1.tif"/></fig></fig-group><p>These data support plasticity in the composition of SEB-activated CD8+ T-cell clusters with HIV-1 infection and ART. We observed the dominance of memory-like clusters with changes in composition and frequency in PLWH on ART, particularly IL-2 expression.</p></sec><sec id="s2-4"><title>Reduction of HIV-1-specific CD8+ T-cell clusters sharing memory-like phenotypes, TIGIT expression and low CD107a</title><p>Next, we characterize HIV-1-specific CD8+ T-cells in PLWH on long-term ART compared to Early infected individuals (Ei), aiming to identify signatures of cellular dysfunction. We performed unsupervised net-SNE analyses in 53,751 cells concatenated, based on the production of at least one functional marker (CD107a, IFNγ, IL-2) in response to HIV-1-Gag peptides combined with lineage markers and IRs (<xref ref-type="fig" rid="fig4">Figure 4A-B</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>). We defined 26 HIV-1-specific clusters by net-SNE analysis. Of note, only three showed significant differences between groups (#1, #2, and #3; <xref ref-type="fig" rid="fig4">Figure 4C-D</xref>). All three clusters decreased in frequency on ART and shared memory-like features (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref>). Clusters #1 and #2 shared co-expression of IRs, mainly PD-1 and TIGIT, low CD107a, IFNγ, and higher expression of IL-2 than #3. Meanwhile, cluster #3 co-express (TIGIT, PD-1, and TIM-3) low expression of IL-2 and higher expression of CD107a and IFNγ (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Although CD107a, IFNγ, and IL-2 expression differed between clusters #1, #2, and #3, all shared TIGIT expression in the context of variable levels of TIM-3. These findings in memory-like clusters, together with the initial ones, accounting for increases in the frequency of TIGIT<sup>+</sup> and TIGIT<sup>+</sup>TIM-3<sup>+</sup> in CM and EFF cells on ART, led us to postulate then as potential markers of HIV-1-specific CD8+ T-cell dysfunction in PLWH on ART.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Unsupervised and supervised analyses of HIV-1-specific CD8+ T-cells.</title><p>(<bold>A</bold>) Gating representation of CD107a, IFNγ, and IL-2 expression in HIV-1-specific CD8+ T-cells (top), net-SNE plots of Ei, S1, S2 and merge groups for HIV-1-specific CD8+ T-cells (bottom). (<bold>B</bold>) Representative net-SNE plots for surface and functional markers. The color gradient displays relative marker expression. (<bold>C</bold>) Unsupervised KNN algorithm for 26 HIV-1-specific clusters color-coded according to the legend. Only clusters with statistical differences are represented in the legend. (<bold>D</bold>) Heatmap of the median biexponential-transformed marker expression normalized to a –3–3 range of respective markers. Asterisks represent the clusters with intergroup statistical differences. (<bold>E</bold>) Scatter plots of intergroup (Ei, S1 and S2) cluster comparisons with significant statistical differences. Data represent the median and interquartile ranges of cluster cell frequency. (<bold>F</bold>) CD107a, IFNγ, and IL-2 frequency of expression in TIGIT+ (upper panel) and TIGIT +TIM-3+ (bottom panel) HIV-1-specific memory CD8+ T-cell subsets. Scatter plots represent the median and interquartile ranges. (<bold>G</bold>) Polyfunctional analyses of CD107a, IFNγ, and IL-2 expression in CM TIGIT HIV-1-specific CD8+ T-cells. Scatter plots represent median and interquartile ranges. We used the Mann-Whitney U test for intergroup analyses and the signed-rank test for intragroup analyses. Holm’s method was used to adjust statistical tests for multiple comparisons. p-values: *&lt;0.05, ***&lt;0.0005, and ****&lt;0.0001. Sample sizes: Ei (21), S1(18), S2 (21).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Unsupervised net-SNE analyses of HIV-1-specific CD8+ T-cells.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83737-fig4-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Cluster cell frequencies from net-SNE analyses of HIV-1-specific CD8+ Tcells per Ei and S (<bold>S1–S2</bold>) study groups.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83737-fig4-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Supervised analyses of CD107a, IFNγ and IL-2 frequencies of HIV-1-specific CD8+ T-cells in Ei and S (<bold>S1–S2</bold>) study groups.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83737-fig4-data3-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata4"><label>Figure 4—source data 4.</label><caption><title>Frequencies of CD107a, IFNγ, and IL-2 expression in TIGIT+ and TIGIT+ TIM-3+HIV-1-specific memory CD8+ T-cell subsets in Ei and S (<bold>S1–S2</bold>) study groups.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83737-fig4-data4-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83737-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Supervised analyses of HIV-1-specific CD8+ T-cell responses.</title><p>(<bold>A</bold>) Frequency of CD107a, IFNγ and IL-2 HIV-1-specific CD8+ T-cells in Ei, S1 and S2. Data represent median and interquartile ranges. (<bold>B</bold>) Table of median frequencies of CD107a, IFNγ and IL-2 HIV-1-specific CD8+ T-cells. We used the Mann-Whitney U test for intergroup analyses and the signed-rank test for intragroup analyses. Holm’s method was used to adjust statistical tests for multiple comparisons. Sample sizes: HC (20), Ei (21), S1(18), S2 (21).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83737-fig4-figsupp1-v1.tif"/></fig></fig-group><p>Despite no significant changes observed in the total frequency of CD107a, IFNγ and IL-2 HIV-1-specific CD8+ T-cell responses between groups (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–B</xref>, <xref ref-type="supplementary-material" rid="fig4sdata3">Figure 4—source data 3</xref>). The analyses of TIGIT and TIGIT +TIM-3 HIV-1-specific memory subsets revealed decreases in the frequency of CD107a TIGIT HIV-1-specific CD8+ T-cells limited to the CM compartment (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, <xref ref-type="supplementary-material" rid="fig4sdata4">Figure 4—source data 4</xref>). No changes in IFNγ and IL-2 were observed. Furthermore, polyfunctional analysis of TIGIT HIV-1-specific CM CD8+ s identified a decrease in monofunctional CD107a<sup>+</sup> as well as in bifunctional CD107a<sup>+</sup>IFNy<sup>+</sup> and CD107<sup>+</sup>IL-2<sup>+</sup> cells overtime on ART (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). Overall, these data support a reduction of HIV-1-specific CD8+ T-cell clusters sharing memory-like phenotypes, TIGIT expression and low CD107a in PLWH on ART.</p></sec><sec id="s2-5"><title>TIGIT blockade restores CD107a expression but not IFNγ or IL-2 production in HIV-1-specific CD8+ T cells</title><p>Then, we decided to explore the blockade of TIGIT and TIM-3 pathways as targets for the recovery of CD107a and potentially IFNγ and IL-2 production in HIV-1-specific CD8+ T-cells. We performed short-term ICB experiments using monoclonal antibodies αTIGIT, αTIM-3, and αTIGIT+ αTIM-3 in PBMC from PLWH on suppressive ART (S) with previous immunophenotype.</p><p>After short-term ICB, we monitored changes in CD107, IFNγ, and IL-2 in total and subsets of HIV-1-specific CD8+ T-cells by flow cytometry (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The Net-SNE TIGIT and TIM-3 projections are represented in <xref ref-type="fig" rid="fig5">Figure 5B</xref> (<xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>). At the level of total HIV-1-specific CD8+ T-cells, short-term ICB experiments demonstrate a specific increase of CD107a expression by αTIGIT (isotype vs. αTIGIT; p&lt;0.05) and αTIGIT + αTIM-3 (isotype vs. αTIGIT + αTIM-3; p&lt;0.05) blockade (<xref ref-type="fig" rid="fig5">Figure 5B</xref>, left). Moreover, the recovery of CD107a by αTIGIT was consistent across HIV-1-specific CD8+ T-cell subsets, being particularly marked for CM (isotype vs. αTIGIT; in CM p&lt;0.005; <xref ref-type="fig" rid="fig5">Figure 5C</xref>) in agreement with our previous findings. Of note, αTIM-3 blockade did not show any effect, and dual blockade of αTIM-3+αTIGIT did not reveal an additive effect (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). No changes in IFNγ and IL-2 production were observed for any conditions tested (<xref ref-type="fig" rid="fig5">Figure 5D–E</xref>, <xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5—source data 2</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Effect of TIGIT, TIM-3, and TIGIT +TIM-3 mAb blockade in HIV-1-specific CD8+ T-cell responses in PLWH on ART.</title><p>(<bold>A</bold>) Representative flow cytometry plots gated on CD8+ T-cells, in the absence of HIV-1 Gag stimulation (basal condition) and presence of HIV-1 Gag stimulation with isotype control, αTIGIT, αTIM-3, and αTIGIT+αTIM-3 antibodies for CD107a, IFNγ and IL-2 expression. (<bold>B</bold>) Representative net-SNE plots for HIV-1-specific CD8+ T-cells from PLWH concatenated and merged according to the condition. (<bold>C–E</bold>) Frequency of CD107a, IFNγ, and IL-2 expression in total and HIV-1-specific CD8+ T-cell subsets for the various conditions tested. The Wilcoxon matched-pairs signed ranked test calculated statistical differences. The data represent the mean of two technical replicates. p-values:=0.05, *&lt;0.05, **&lt;0.005 and ***&lt;0.0005. Sample sizes: S1(10), S2 (10).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Unsupervised net-SNE analyses for HIV-1-specific CD8+ T-cells in PLWH on ART.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83737-fig5-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Frequencies of CD107a, IFNγ, and IL-2 expression in total and subsets of HIV-1-specific CD8+ T-cells in PLWH on ART.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83737-fig5-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83737-fig5-v1.tif"/></fig><p>These data support heterogeneity in the functional recovery of HIV-1-specific CD8+ T-cells by differentiation stage based on αTIGIT, αTIM-3, and αTIGIT+αTIM-3 blockade. Overall, these results identify the targeting of TIGIT to recover the degranulation in HIV-1-specific CD8+ T-cells, particularly within the CM compartment in PLWH on ART.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>CD8+ Tex displays a range of functional defects in PLWH early in HIV-1 infection and during ART (<xref ref-type="bibr" rid="bib57">Sekine et al., 2020</xref>; <xref ref-type="bibr" rid="bib12">Buggert et al., 2014</xref>; <xref ref-type="bibr" rid="bib7">Bengsch et al., 2016</xref>; <xref ref-type="bibr" rid="bib58">Sen et al., 2016</xref>). The expression of IRs is a hallmark of Tex (<xref ref-type="bibr" rid="bib11">Breton et al., 2013</xref>; <xref ref-type="bibr" rid="bib19">Cockerham et al., 2014</xref>; <xref ref-type="bibr" rid="bib52">Rutishauser et al., 2017</xref>; <xref ref-type="bibr" rid="bib34">Jiang et al., 2020</xref>), and co-expression of IRs has been associated with HIV-1 disease progression (<xref ref-type="bibr" rid="bib33">Hoffmann et al., 2016</xref>; <xref ref-type="bibr" rid="bib16">Chew et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Gupta et al., 2015</xref>; <xref ref-type="bibr" rid="bib36">Jones et al., 2008</xref>; <xref ref-type="bibr" rid="bib64">Tian et al., 2015</xref>) and cancer severity (<xref ref-type="bibr" rid="bib14">Chauvin et al., 2015</xref>; <xref ref-type="bibr" rid="bib3">Anderson et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Joller and Kuchroo, 2017</xref>). Although ICB has demonstrated promising results in cancer remission (<xref ref-type="bibr" rid="bib68">Vaddepally et al., 2020</xref>; <xref ref-type="bibr" rid="bib66">Twomey and Zhang, 2021</xref>), its applicability in HIV-1 as a cure intervention remains unclear (<xref ref-type="bibr" rid="bib9">Blanch-Lombarte et al., 2019</xref>; <xref ref-type="bibr" rid="bib24">Fromentin et al., 2019</xref>; <xref ref-type="bibr" rid="bib39">Le Garff et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Gay et al., 2017</xref>; <xref ref-type="bibr" rid="bib30">Guihot et al., 2018</xref>; <xref ref-type="bibr" rid="bib67">Uldrick et al., 2022</xref>). Therefore, it is essential to understand the patterns of IRs expression and function across the CD8+ T-cell landscape to identify targets for ICB broadly applicable to PLWH on ART (<xref ref-type="bibr" rid="bib22">Deeks et al., 2021</xref>).</p><p>Here, we immunophenotype CD8+ T-cells using five IRs and three functional markers in PLWH over the ten years of ART. In this way, we overcome previous study limitations based on single IRs expression, bulk CD8+ T-cells, and cross-sectional data (<xref ref-type="bibr" rid="bib11">Breton et al., 2013</xref>; <xref ref-type="bibr" rid="bib52">Rutishauser et al., 2017</xref>; <xref ref-type="bibr" rid="bib16">Chew et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Gupta et al., 2015</xref>; <xref ref-type="bibr" rid="bib64">Tian et al., 2015</xref>). Our results demonstrated a marked and significant increase in TIGIT CD8+ T-cells, particularly within the central memory compartment, not ameliorated by long-term ART. Also, TIGIT CD8+ T-cells negatively correlated with CD4+ counts in PLWH on ART. These data support continuous expression of TIGIT despite ART in agreement with previous studies (<xref ref-type="bibr" rid="bib61">Tauriainen et al., 2017</xref>; <xref ref-type="bibr" rid="bib16">Chew et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Jones et al., 2008</xref>; <xref ref-type="bibr" rid="bib3">Anderson et al., 2016</xref>; <xref ref-type="bibr" rid="bib56">Schildberg et al., 2016</xref>) and uncover novel associations between TIGIT expression in CD8+ T-cells and poorer immune status in PLWH on ART. Thus, these data indicate a specific contribution of TIGIT expression to persistent immune activation and poor CD4+ recovery on ART.</p><p>In contrast, we observed transient increases of PD-1, LAG-3, TIM-3, and CD39 expression in total, memory and effector CD8+ T-cells that normalize over time on ART. The potential biological implications of such a difference may relate to the nature of each receptor and the specific immune regulatory pathway activated during HIV-1 infection and ART. Also, these divergences may be influenced by the presence of γ-chain cytokines, such us IL-2, IL-15, and IL-21, in plasma able to upregulate the TIGIT expression in CD8+ T-cells (<xref ref-type="bibr" rid="bib16">Chew et al., 2016</xref>). A previous study demonstrated an association between high levels of IL-15 and high TIGIT expression in CD4+ T-cells with suboptimal CD4+ recovery in PLWH on ART (<xref ref-type="bibr" rid="bib48">Pino et al., 2021</xref>).</p><p>Our study combined high-dimensional supervised and unsupervised analysis providing an unprecedented deep immunophenotype of the CD8+ T-cell landscape in PLWH over a decade on ART. We explored complementary levels of complexity for the characterization of CD8+ T-cells, including an absence of stimuli (bulk), the presence of antigen-independent stimuli (SEB), and the presence of antigen-specific stimuli (HIV-1).</p><p>In the absence of stimuli, supervised analyses confirmed heterogeneous and complex patterns of IRs co-expression across CD8+ T-cell lineages altered by HIV-1 infection and shaped by ART (<xref ref-type="bibr" rid="bib57">Sekine et al., 2020</xref>; <xref ref-type="bibr" rid="bib73">Yamamoto et al., 2011</xref>; <xref ref-type="bibr" rid="bib36">Jones et al., 2008</xref>; <xref ref-type="bibr" rid="bib44">Noyan et al., 2018</xref>; <xref ref-type="bibr" rid="bib6">Avery et al., 2018</xref>). Furthermore, unsupervised analyses added complexity to previous data by delineating in profound detail early and continuous changes of contraction and expansion of cellular clusters with HIV-1 infection and time on ART. We tracked memory-like expansion and effector-like cluster contraction over time on ART according to the establishment of memory responses. Similarly, in the presence of antigen-independent stimuli, we identified continuous changes in cellular cluster composition by contraction and expansion of CD8+ cellular cluster with infection and treatment. We observed a dominance of memory-like clusters with changes in composition and frequency tracked by an augment of IL-2 expressing clusters on ART both by supervised and unsupervised analyses. The IL-2 expression regulates proliferation and homeostasis and contributes to the generation of long-term memory responses (<xref ref-type="bibr" rid="bib63">Teigler et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Kou et al., 1998</xref>; <xref ref-type="bibr" rid="bib17">Chiu et al., 2022</xref>), suggesting a partial functional remodelling of CD8+ T-cell populations independent of antigen in PLWH over time on ART. Thus, our findings support the contribution of IRs co-expression in CD8+ Tex and T-cell activation favouring a continuous reshaping of memory and effector-like CD8+ cellular clusters. These findings indicate the enormous plasticity and constant homeostasis of CD8+ T-cells in PLWH during a decade of ART (<xref ref-type="bibr" rid="bib71">Warren et al., 2019</xref>).</p><p>In the presence of HIV-1-specific stimuli, supervised and unsupervised analyses delineate a reduction of HIV-1-specific CD8+ T cells sharing memory phenotypes, TIGIT expression and low CD107a. Our findings focused on the memory compartment of TIGIT expressing HIV-1-specific CD8+ T-cells demonstrating a decrease in monofunctional CD107a<sup>+</sup> and bifunctional CD107a<sup>+</sup>IFNγ<sup>+</sup> and CD107a<sup>+</sup>IL-2<sup>+</sup> cells. Previous studies support a direct correlation between monofunctional CD107a<sup>+</sup> and Eomes intensity in exhausted HIV-1-specific CD8+ T-cells (<xref ref-type="bibr" rid="bib12">Buggert et al., 2014</xref>). Although this study did not include the expression of TIGIT across analyses, it may suggest an association between TIGIT expression and the T-bet /Eomes axis in charge of regulating the exhaustion and memory cell fate of CD8+ T-cells (<xref ref-type="bibr" rid="bib23">Doering et al., 2012</xref>).</p><p>Our findings further support the role of TIGIT as a signature of dysfunctional and Tex antiviral responses (<xref ref-type="bibr" rid="bib16">Chew et al., 2016</xref>). Indeed, the blockade of the TIGIT pathway restored CD107a expression in HIV-1-specific CD8+ T-cells across cellular compartments with a marked effect in the central memory compartment according to our findings from HIV-1-specific immunophenotype of TIGIT CD8+ T-cells. To our knowledge, our study is the first to demonstrate the recovery of CD107a expression in HIV-1-specific CD8+ T-cells by TIGIT blockade. These data contrast with Chew et al., which observed the recovery of IFNγ production by TIGIT blockade. However, they also reported a reduction in CD107a expression in TIGIT+ CD8 T-cells in response to aCD3/aCD28 activation, supporting a dysfunctional profile of TIGIT+ CD8+ T-cells. Differences between study groups accounting for time on ART, samples tested and interindividual variability of in vitro ICB experiments may account for some of the differences observed.</p><p>Although the mechanistic behind TIGIT signalling and CD107a expression are not fully understood, low CD107a expression has been linked to the terminal T-bet<sup>dim</sup>Eomes<sup>hi</sup> exhausted phenotype, and HIV-1-specific CD8+ T-cells expressing TIGIT can degranulate to a certain extent (<xref ref-type="bibr" rid="bib12">Buggert et al., 2014</xref>; <xref ref-type="bibr" rid="bib61">Tauriainen et al., 2017</xref>). Moreover, our data did not support an additive effect recovering HIV-1-specific CD8+ T-cells function of TIGIT and TIM-3 combinatorial blockade over TIGIT blockade. The redundancy and promiscuity of TIM-3 for several ligands, including Gal-9, CEACAM-1, PtdSer, and HMGB-1 (<xref ref-type="bibr" rid="bib4">Andrews et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Sabatos-Peyton et al., 2018</xref>), may be associated with these results. We cannot exclude the impact of TIGIT and TIM-3 blockade in other cell types (<xref ref-type="bibr" rid="bib3">Anderson et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Joller and Kuchroo, 2017</xref>; <xref ref-type="bibr" rid="bib45">Pende et al., 2006</xref>).</p><p>We acknowledge several study limitations; First, the sample size of study groups and the use of peripheral blood samples underestimate the potential contribution of TIGIT expression to Tex in lymphoid tissues. Second, the use of only Gag as stimuli for the characterization of HV-1-specific CD8+ T- cell responses in the absence of TCR sequencing. Using alternative HIV-1 antigens such as Nef, Env or Pol may provide additional information on the profile of CD8+ T-cell functional responses against early and late-expressed viral proteins in PLWH on ART (<xref ref-type="bibr" rid="bib37">Kløverpris et al., 2013</xref>; <xref ref-type="bibr" rid="bib60">Stevenson et al., 2021</xref>). Third, limited ICB experiments to CD107a, INFγ and IL-2 functional markers without complementary cytotoxic markers (perforin, granzyme B). Forth, complementary transcriptomic, epigenetic, and metabolic markers are needed for a complete description of Tex’s immune signatures linked to TIGIT expression in HIV-1 specific CD8+ T-cells in PLWH on ART.</p><p>In summary, our study profile with unprecedented detail continuous reshaping of memory-like and effector-like of CD8+ T cellular clusters in PLWH over a decade of ART. The study identifies the TIGIT as a critical target for Tex associated with the loss of CD107a expression in HIV-1-specific CD8+ T-cells. These findings support targeting the TIGIT/CD155 axis for Tex precision immune-base curative interventions in PLWH at all ART stages.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Study groups</title><p>This retrospective study analyzed clinical data and biological sample availability from 3000 patients assigned to the HIV-1 clinical unit of the Germans Trias i Pujol University Hospital. We included individuals with cryopreserved PBMCs available in our collection. We identified 24 chronically HIV-1-infected individuals who had been treated mainly with a combination of NNRTI and NRTI for more than ten years with sustained virological suppression (&lt;50 HIV-1-RNA copies/ml) and with longitudinal biological samples at timepoint 1 (S1), 2.2 (1.8–2.8) years undetectable on ART, and at time point 2 (S2), 10.1 (7.4–12.9) years undetectable on ART (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, <xref ref-type="fig" rid="fig1">Figure 1A</xref>, Source data <xref ref-type="fig" rid="fig1">Figure 1A</xref>). We excluded individuals with integrase inhibitors, ART as monotherapy, and treatments with mitochondrial toxicity, including Trizivir, d4T, ddI, AZT and blips over the ART period (S1- S2) to ensure homogeneous treatment over time. For comparative purposes, we included 24 early HIV-1-infected individuals (Ei) defined in a window of 1.3 (0.77–17.8) weeks after seroconversion in the absence of ART and 24 healthy controls (HC). The groups were balanced by age to the S2 samples to avoid confounding effects on IR expression.</p></sec><sec id="s4-2"><title>CD8+ T-cell immunophenotype</title><p>Cryopreserved PBMCs from the study groups were thawed and rested overnight at 37 °C in a 5% CO<sub>2</sub> incubator. The following day, PBMCs were incubated for six hours at 37 °C in a 5% CO<sub>2</sub> incubator under RPMI complemented medium 10% FBS in the presence of CD28/49d co-stimulatory molecules (1 μl/ml, BD), Monensin A (1 μl/ml, BD Golgi STOP), and anti-human antibody for CD107a (PE-Cy5, clone H4A3, Thermo Fisher Scientific). PBMCs were left unstimulated, stimulated with SEB (1 μg/ml, Sigma-Aldrich), and stimulated with HIV-1-Gag peptide pool (2 μg/peptide/ml, EzBiolab). After six hours of stimulation, cells were rested overnight at 4 °C as previously described (<xref ref-type="bibr" rid="bib9">Blanch-Lombarte et al., 2019</xref>). The next day, PBMCs were washed with PBS 1 X and stained for 25 min with the Live/Dead probe (APC-Cy7, Thermo Fisher Scientific) at RT to discriminate dead cells. Cells were washed with PBS 1 X and surface stained with antibodies for 25 minutes at RT. We used CD3 (A700, clone UCHT1, BD), CD4 (APC-Cy7, clone SK3, BD), CD8 (V500, clone RPA-T8, BD), CD45RA (BV786, clone HI100, BD), CCR7 (PE-CF594, clone 150503, BD), CD27 (BV605, clone L128, BD), TIGIT (PE-Cy7, clone MBSA43, Labclinics SA), PD-1 (BV421, clone EH12.1, BD), LAG-3 (PE, clone T47-530, BD), TIM-3 (A647, clone 7D3, BD) and CD39 (FITC, clone TU66, BD) antibodies. Afterwards, cells were washed twice in PBS 1 X, fixed, and permeabilized with Fix/Perm kit (A and B solutions, Thermo Fisher Scientific) for intracellular cytokine staining with anti-human antibodies of IFNγ (BV711, clone B27, BD) and IL-2 (BV650, clone MQ1-17H12, BD). Finally, stained cells were washed twice with PBS 1 X and fixed in formaldehyde 1%.</p></sec><sec id="s4-3"><title>TIGIT, TIM-3 and TIGIT+TIM-3 short-term checkpoint blockade</title><p>We selected cryopreserved PBMCs from S1 (n=10) and S2 (n=10). Samples were previously characterized by the expression of TIGIT and TIM-3 on total CD8+ T-cells. PBMCs were thawed and rested for four hours at 37 °C in a 5% CO<sub>2</sub> incubator. Next, cells were incubated under RPMI complemented medium 10% FBS with 1 μl/ml of anti-CD28/CD49d and 1 μl/ml of Monensin A overnight at 37 °C in a 5% CO<sub>2</sub>. PBMCs are divided in the following conditions; (1) unstimulated, (2) SEB (1 μg/ml, Sigma-Aldrich) and (3) HIV-1-Gag peptide pool (2 μg/peptide/ml) in the absence or presence of αTIGIT and/or αTIM-3, and its respective isotype antibodies. For the single blockade of TIGIT (αTIGIT), we included Ultra-LEAF purified anti-human TIGIT antibody (10 μg/ml, clone A15153G, Biolegend) or its control isotype Ultra-LEAF purified mouse IgG2a antibody (10 μg/ml, MOPC-173, Biolegend). For single TIM-3 blockade (αTIM-3), we used Ultra-LEAF purified anti-human TIM-3 antibody (10 μg/ml, clone F38-2E2, Biolegend) or its respective isotype Ultra-LEAF purified mouse IgG1 antibody (10 μg/ml, MOPC-21, Biolegend). Finally, we included αTIGIT+αTIM-3 or their respective IgG2 + IgG1 isotypes for a combinational blockade. The next day, PBMCs were surface and intracellularly stained with the panel of antibodies and the methodology described in the section above.</p></sec><sec id="s4-4"><title>Supervised immunophenotype data analysis</title><p>Stained PBMCs were acquired on an LSR Fortessa cytometer using FACSDiVa software (BD). Approximately 1,000,000 events of PBMCs were recorded per specimen. Antibody capture beads (BD) were used for single-stain compensation controls. Flow cytometry data were analyzed with FlowJo software v10.6.1, and fluorescence minus one (FMO) was used to set manual gates. We analyzed CD8+ T-cells by excluding dump and CD4+ T-cells. We excluded patients with &lt;20% viability in lymphocytes and total CD8+ T-cells (Source data <xref ref-type="fig" rid="fig1">Figure 1A</xref>). As previously described, we measured by supervised and classical analyses the IRs expression in CD8+ T-cell subsets, including Naive, central memory, transitional memory, effector memory, and effector CD8+ T-cells (<xref ref-type="bibr" rid="bib11">Breton et al., 2013</xref>; <xref ref-type="bibr" rid="bib9">Blanch-Lombarte et al., 2019</xref>). We performed two technical replicates for SEB-activated and HIV-1-specific CD8+ T-cell cytokine production. We considered the cytokine response positive after background subtraction (mean of two technical replicates) used as the cut-off value. For each independent sample, we recorded a median of 1,000 events and 50 events positive for cytokines for total and CD8+ T-cell subsets, respectively.</p></sec><sec id="s4-5"><title>Unsupervised immunophenotype data analysis</title><p>The phenotypic and functional characterization of cellular populations was analyzed by using t-Distributed Stochastic Neighbor Embedding (t-SNE; <xref ref-type="bibr" rid="bib69">van der Maaten, 2008</xref>) and net-SNE (<xref ref-type="bibr" rid="bib18">Cho et al., 2018</xref>) dimensionality reduction algorithms to visualize single-cell distributions in two-dimensional maps. Briefly, cell intensity was z-normalized, and a randomly selected subset of cells, at least 1000 cells per sample, was passed through the t-SNE algorithm. The resulting t-SNE dimension was then used to predict the position of all remaining CD8+ T-cells acquired per sample from each group using the net-SNE algorithm based on neural networks. For functional analysis, we selected polyclonally activated and HIV-1-specific CD8+ T-cells producing at least one cytokine CD107a, IFNγ, or IL-2 under SEB or HIV-1 conditions, respectively. In parallel, we discovered cell communities using the Phenograph clustering technique. It operates by computing the Jaccard coefficient between nearest neighbours, which was set to 30 in all executions, and then locating cell communities (or clusters) using the Louvain method. The method creates a network indicating phenotypic similarities between cells. The netSNE maps included representations of the identified cell communities, and additionally, we built a heatmap with the clusters in the columns and the markers of interest in the rows to better comprehend the phenotypical interpretation of each cluster. The color scale displays each marker’s median intensity on a biexponential scale. We calculated quantitative assessments of cellular clusters in the percentage of cells for each sample to analyze and compare the distribution between HC, Ei, S1, and S2 groups, similar to the classical flow cytometry analysis.</p></sec><sec id="s4-6"><title>Statistics</title><p>Bivariate analysis was conducted using nonparametric methods as follows: Mann-Whitney U test for independent median comparison between groups, Wilcoxon signed-rank test for paired median changes over time, permutation test for composition distribution between groups, Kruskal-Wallis test for comparison between more than two groups, and spearman linear correlation coefficient to study the association between continuous variables. Holm’s method was used when appropriate to adjust statistical tests for multiple comparisons with a significance level of 0.05. All statistics and single-cell analyses were conducted using the R statistical package (<xref ref-type="bibr" rid="bib49">R Development Core Team, 2008</xref>). The selection of clusters was performed through the significant differences obtained by inter- and intragroup comparisons between groups. Moreover, pattern distribution and graphical representations of all possible Boolean combinations for IRs co-expression and functional markers were conducted using the data analysis program Pestle v2.0 and SPICE v6.0 software (<xref ref-type="bibr" rid="bib50">Roederer et al., 2011</xref>). Graph plotting was performed by GraphPad Prism v8.0 software and R packages. The data represents the mean of two technical replicates.</p></sec><sec id="s4-7"><title>Study approval</title><p>The study was conducted according to the principles of the Declaration of Helsinki (<xref ref-type="bibr" rid="bib72">World Medical Association, 2013</xref>). The Hospital Germans Trias i Pujol Ethics Committee approved all experimental protocols (PI14-084). For the study, subjects provided written informed consent for research purposes of biological samples taken from them.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Supervision, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Software, Formal analysis, Validation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con6"><p>Methodology</p></fn><fn fn-type="con" id="con7"><p>Software, Methodology</p></fn><fn fn-type="con" id="con8"><p>Software, Methodology</p></fn><fn fn-type="con" id="con9"><p>Software, Methodology</p></fn><fn fn-type="con" id="con10"><p>Funding acquisition, Investigation, Project administration</p></fn><fn fn-type="con" id="con11"><p>Recruited the study participants</p></fn><fn fn-type="con" id="con12"><p>Software, Methodology</p></fn><fn fn-type="con" id="con13"><p>Recruited the study participants</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: The study was conducted according to the principles expressed in the Declaration of Helsinki (Fortaleza, 2013). The Hospital Germans Trias i Pujol Ethics Committee approved all experimental protocols (PI14-084). For the study, subjects provided their written informed consent for research purposes of biological samples taken from them.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>The epidemiological and clinical characteristics of the study groups.</title></caption><media xlink:href="elife-83737-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83737-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The data supporting the findings of this study are available within the paper and its supplementary information files. Source data are provided in this paper.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank the Flow Cytometry Core Facility from the Germans Trias i Pujol Research Institute (IGTP).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akdis</surname><given-names>M</given-names></name><name><surname>Aab</surname><given-names>A</given-names></name><name><surname>Altunbulakli</surname><given-names>C</given-names></name><name><surname>Azkur</surname><given-names>K</given-names></name><name><surname>Costa</surname><given-names>RA</given-names></name><name><surname>Crameri</surname><given-names>R</given-names></name><name><surname>Duan</surname><given-names>S</given-names></name><name><surname>Eiwegger</surname><given-names>T</given-names></name><name><surname>Eljaszewicz</surname><given-names>A</given-names></name><name><surname>Ferstl</surname><given-names>R</given-names></name><name><surname>Frei</surname><given-names>R</given-names></name><name><surname>Garbani</surname><given-names>M</given-names></name><name><surname>Globinska</surname><given-names>A</given-names></name><name><surname>Hess</surname><given-names>L</given-names></name><name><surname>Huitema</surname><given-names>C</given-names></name><name><surname>Kubo</surname><given-names>T</given-names></name><name><surname>Komlosi</surname><given-names>Z</given-names></name><name><surname>Konieczna</surname><given-names>P</given-names></name><name><surname>Kovacs</surname><given-names>N</given-names></name><name><surname>Kucuksezer</surname><given-names>UC</given-names></name><name><surname>Meyer</surname><given-names>N</given-names></name><name><surname>Morita</surname><given-names>H</given-names></name><name><surname>Olzhausen</surname><given-names>J</given-names></name><name><surname>O’Mahony</surname><given-names>L</given-names></name><name><surname>Pezer</surname><given-names>M</given-names></name><name><surname>Prati</surname><given-names>M</given-names></name><name><surname>Rebane</surname><given-names>A</given-names></name><name><surname>Rhyner</surname><given-names>C</given-names></name><name><surname>Rinaldi</surname><given-names>A</given-names></name><name><surname>Sokolowska</surname><given-names>M</given-names></name><name><surname>Stanic</surname><given-names>B</given-names></name><name><surname>Sugita</surname><given-names>K</given-names></name><name><surname>Treis</surname><given-names>A</given-names></name><name><surname>van de Veen</surname><given-names>W</given-names></name><name><surname>Wanke</surname><given-names>K</given-names></name><name><surname>Wawrzyniak</surname><given-names>M</given-names></name><name><surname>Wawrzyniak</surname><given-names>P</given-names></name><name><surname>Wirz</surname><given-names>OF</given-names></name><name><surname>Zakzuk</surname><given-names>JS</given-names></name><name><surname>Akdis</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases</article-title><source>Journal of Allergy and Clinical Immunology</source><volume>138</volume><fpage>984</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2016.06.033</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aktas</surname><given-names>E</given-names></name><name><surname>Kucuksezer</surname><given-names>UC</given-names></name><name><surname>Bilgic</surname><given-names>S</given-names></name><name><surname>Erten</surname><given-names>G</given-names></name><name><surname>Deniz</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Relationship between CD107a expression and cytotoxic activity</article-title><source>Cellular Immunology</source><volume>254</volume><fpage>149</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2008.08.007</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>AC</given-names></name><name><surname>Joller</surname><given-names>N</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation</article-title><source>Immunity</source><volume>44</volume><fpage>989</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.05.001</pub-id><pub-id pub-id-type="pmid">27192565</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>LP</given-names></name><name><surname>Yano</surname><given-names>H</given-names></name><name><surname>Vignali</surname><given-names>DAA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups</article-title><source>Nature Immunology</source><volume>20</volume><fpage>1425</fpage><lpage>1434</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0512-0</pub-id><pub-id pub-id-type="pmid">31611702</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attanasio</surname><given-names>J</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>HIV infection is associated with downregulation of btla expression on mycobacterium tuberculosis-specific CD4 T cells in active tuberculosis disease</article-title><source>Frontiers in Immunology</source><volume>44</volume><fpage>1052</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01983</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avery</surname><given-names>L</given-names></name><name><surname>Filderman</surname><given-names>J</given-names></name><name><surname>Szymczak-Workman</surname><given-names>AL</given-names></name><name><surname>Kane</surname><given-names>LP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion</article-title><source>PNAS</source><volume>115</volume><fpage>2455</fpage><lpage>2460</lpage><pub-id pub-id-type="doi">10.1073/pnas.1712107115</pub-id><pub-id pub-id-type="pmid">29463725</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bengsch</surname><given-names>B</given-names></name><name><surname>Johnson</surname><given-names>AL</given-names></name><name><surname>Kurachi</surname><given-names>M</given-names></name><name><surname>Odorizzi</surname><given-names>PM</given-names></name><name><surname>Pauken</surname><given-names>KE</given-names></name><name><surname>Attanasio</surname><given-names>J</given-names></name><name><surname>Stelekati</surname><given-names>E</given-names></name><name><surname>McLane</surname><given-names>LM</given-names></name><name><surname>Paley</surname><given-names>MA</given-names></name><name><surname>Delgoffe</surname><given-names>GM</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion</article-title><source>Immunity</source><volume>45</volume><fpage>358</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.07.008</pub-id><pub-id pub-id-type="pmid">27496729</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhat</surname><given-names>P</given-names></name><name><surname>Leggatt</surname><given-names>G</given-names></name><name><surname>Waterhouse</surname><given-names>N</given-names></name><name><surname>Frazer</surname><given-names>IH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity</article-title><source>Cell Death &amp; Disease</source><volume>8</volume><elocation-id>e2836</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2017.67</pub-id><pub-id pub-id-type="pmid">28569770</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanch-Lombarte</surname><given-names>O</given-names></name><name><surname>Gálvez</surname><given-names>C</given-names></name><name><surname>Revollo</surname><given-names>B</given-names></name><name><surname>Jiménez-Moyano</surname><given-names>E</given-names></name><name><surname>Llibre</surname><given-names>JM</given-names></name><name><surname>Manzano</surname><given-names>JL</given-names></name><name><surname>Boada</surname><given-names>A</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>E Speiser</surname><given-names>D</given-names></name><name><surname>Clotet</surname><given-names>B</given-names></name><name><surname>Prado</surname><given-names>JG</given-names></name><name><surname>Martinez-Picado</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Enhancement of antiviral CD8<sup>+</sup> T-Cell responses and complete remission of metastatic melanoma in an HIV-1-Infected subject treated with pembrolizumab</article-title><source>Journal of Clinical Medicine</source><volume>8</volume><elocation-id>2089</elocation-id><pub-id pub-id-type="doi">10.3390/jcm8122089</pub-id><pub-id pub-id-type="pmid">31805700</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrow</surname><given-names>P</given-names></name><name><surname>Lewicki</surname><given-names>H</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Oldstone</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection</article-title><source>Journal of Virology</source><volume>68</volume><fpage>6103</fpage><lpage>6110</lpage><pub-id pub-id-type="doi">10.1128/JVI.68.9.6103-6110.1994</pub-id><pub-id pub-id-type="pmid">8057491</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breton</surname><given-names>G</given-names></name><name><surname>Chomont</surname><given-names>N</given-names></name><name><surname>Takata</surname><given-names>H</given-names></name><name><surname>Fromentin</surname><given-names>R</given-names></name><name><surname>Ahlers</surname><given-names>J</given-names></name><name><surname>Filali-Mouhim</surname><given-names>A</given-names></name><name><surname>Riou</surname><given-names>C</given-names></name><name><surname>Boulassel</surname><given-names>MR</given-names></name><name><surname>Routy</surname><given-names>JP</given-names></name><name><surname>Yassine-Diab</surname><given-names>B</given-names></name><name><surname>Sékaly</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection</article-title><source>Journal of Immunology</source><volume>191</volume><fpage>2194</fpage><lpage>2204</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1200646</pub-id><pub-id pub-id-type="pmid">23918986</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buggert</surname><given-names>M</given-names></name><name><surname>Tauriainen</surname><given-names>J</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Frederiksen</surname><given-names>J</given-names></name><name><surname>Ivarsson</surname><given-names>MA</given-names></name><name><surname>Michaëlsson</surname><given-names>J</given-names></name><name><surname>Lund</surname><given-names>O</given-names></name><name><surname>Hejdeman</surname><given-names>B</given-names></name><name><surname>Jansson</surname><given-names>M</given-names></name><name><surname>Sönnerborg</surname><given-names>A</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name><name><surname>Betts</surname><given-names>MR</given-names></name><name><surname>Karlsson</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection</article-title><source>PLOS Pathogens</source><volume>10</volume><elocation-id>e1004251</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004251</pub-id><pub-id pub-id-type="pmid">25032686</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cartwright</surname><given-names>EK</given-names></name><name><surname>Spicer</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>SA</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Fast</surname><given-names>R</given-names></name><name><surname>Paganini</surname><given-names>S</given-names></name><name><surname>Lawson</surname><given-names>BO</given-names></name><name><surname>Nega</surname><given-names>M</given-names></name><name><surname>Easley</surname><given-names>K</given-names></name><name><surname>Schmitz</surname><given-names>JE</given-names></name><name><surname>Bosinger</surname><given-names>SE</given-names></name><name><surname>Paiardini</surname><given-names>M</given-names></name><name><surname>Chahroudi</surname><given-names>A</given-names></name><name><surname>Vanderford</surname><given-names>TH</given-names></name><name><surname>Estes</surname><given-names>JD</given-names></name><name><surname>Lifson</surname><given-names>JD</given-names></name><name><surname>Derdeyn</surname><given-names>CA</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CD8(+) lymphocytes are required for maintaining viral suppression in siv-infected macaques treated with short-term antiretroviral therapy</article-title><source>Immunity</source><volume>45</volume><fpage>656</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.08.018</pub-id><pub-id pub-id-type="pmid">27653601</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chauvin</surname><given-names>JM</given-names></name><name><surname>Pagliano</surname><given-names>O</given-names></name><name><surname>Fourcade</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Chen</surname><given-names>TT</given-names></name><name><surname>Maurer</surname><given-names>M</given-names></name><name><surname>Korman</surname><given-names>AJ</given-names></name><name><surname>Zarour</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>TIGIT and PD-1 impair tumor antigen-specific CD8</article-title><source>The Journal of Clinical Investigation</source><volume>125</volume><fpage>2046</fpage><lpage>2058</lpage><pub-id pub-id-type="doi">10.1172/JCI80445</pub-id><pub-id pub-id-type="pmid">25866972</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Moussa</surname><given-names>M</given-names></name><name><surname>Catalfamo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The role of immunomodulatory receptors in the pathogenesis of hiv infection: a therapeutic opportunity for hiv cure?</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>1223</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.01223</pub-id><pub-id pub-id-type="pmid">32714317</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chew</surname><given-names>GM</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Webb</surname><given-names>GM</given-names></name><name><surname>Burwitz</surname><given-names>BJ</given-names></name><name><surname>Wu</surname><given-names>HL</given-names></name><name><surname>Reed</surname><given-names>JS</given-names></name><name><surname>Hammond</surname><given-names>KB</given-names></name><name><surname>Clayton</surname><given-names>KL</given-names></name><name><surname>Ishii</surname><given-names>N</given-names></name><name><surname>Abdel-Mohsen</surname><given-names>M</given-names></name><name><surname>Liegler</surname><given-names>T</given-names></name><name><surname>Mitchell</surname><given-names>BI</given-names></name><name><surname>Hecht</surname><given-names>FM</given-names></name><name><surname>Ostrowski</surname><given-names>M</given-names></name><name><surname>Shikuma</surname><given-names>CM</given-names></name><name><surname>Hansen</surname><given-names>SG</given-names></name><name><surname>Maurer</surname><given-names>M</given-names></name><name><surname>Korman</surname><given-names>AJ</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Sacha</surname><given-names>JB</given-names></name><name><surname>Ndhlovu</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection</article-title><source>PLOS Pathogens</source><volume>12</volume><elocation-id>e1005349</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005349</pub-id><pub-id pub-id-type="pmid">26741490</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>CY</given-names></name><name><surname>Chang</surname><given-names>JJ</given-names></name><name><surname>Dantanarayana</surname><given-names>AI</given-names></name><name><surname>Solomon</surname><given-names>A</given-names></name><name><surname>Evans</surname><given-names>VA</given-names></name><name><surname>Pascoe</surname><given-names>R</given-names></name><name><surname>Gubser</surname><given-names>C</given-names></name><name><surname>Trautman</surname><given-names>L</given-names></name><name><surname>Fromentin</surname><given-names>R</given-names></name><name><surname>Chomont</surname><given-names>N</given-names></name><name><surname>McMahon</surname><given-names>JH</given-names></name><name><surname>Cameron</surname><given-names>PU</given-names></name><name><surname>Rasmussen</surname><given-names>TA</given-names></name><name><surname>Lewin</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Combination immune checkpoint blockade enhances IL-2 and CD107a production from HIV-Specific T cells ex vivo in people living with hiv on antiretroviral therapy</article-title><source>Journal of Immunology</source><volume>208</volume><fpage>54</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2100367</pub-id><pub-id pub-id-type="pmid">34853078</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Berger</surname><given-names>B</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Generalizable and scalable visualization of single-cell data using neural networks</article-title><source>Cell Systems</source><volume>7</volume><fpage>185</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2018.05.017</pub-id><pub-id pub-id-type="pmid">29936184</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cockerham</surname><given-names>LR</given-names></name><name><surname>Jain</surname><given-names>V</given-names></name><name><surname>Sinclair</surname><given-names>E</given-names></name><name><surname>Glidden</surname><given-names>DV</given-names></name><name><surname>Hartogenesis</surname><given-names>W</given-names></name><name><surname>Hatano</surname><given-names>H</given-names></name><name><surname>Hunt</surname><given-names>PW</given-names></name><name><surname>Martin</surname><given-names>JN</given-names></name><name><surname>Pilcher</surname><given-names>CD</given-names></name><name><surname>Sekaly</surname><given-names>R</given-names></name><name><surname>McCune</surname><given-names>JM</given-names></name><name><surname>Hecht</surname><given-names>FM</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Programmed death-1 expression on CD4</article-title><source>AIDS</source><volume>28</volume><fpage>1749</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000314</pub-id><pub-id pub-id-type="pmid">24871455</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>DR</given-names></name><name><surname>Gaiha</surname><given-names>GD</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>CD8+ T cells in HIV control, cure and prevention</article-title><source>Nature Reviews Immunology</source><volume>20</volume><fpage>471</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0274-9</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Day</surname><given-names>CL</given-names></name><name><surname>Kaufmann</surname><given-names>DE</given-names></name><name><surname>Kiepiela</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>JA</given-names></name><name><surname>Moodley</surname><given-names>ES</given-names></name><name><surname>Reddy</surname><given-names>S</given-names></name><name><surname>Mackey</surname><given-names>EW</given-names></name><name><surname>Miller</surname><given-names>JD</given-names></name><name><surname>Leslie</surname><given-names>AJ</given-names></name><name><surname>DePierres</surname><given-names>C</given-names></name><name><surname>Mncube</surname><given-names>Z</given-names></name><name><surname>Duraiswamy</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Eichbaum</surname><given-names>Q</given-names></name><name><surname>Altfeld</surname><given-names>M</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name><name><surname>Coovadia</surname><given-names>HM</given-names></name><name><surname>Goulder</surname><given-names>PJR</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression</article-title><source>Nature</source><volume>443</volume><fpage>350</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1038/nature05115</pub-id><pub-id pub-id-type="pmid">16921384</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Archin</surname><given-names>N</given-names></name><name><surname>Cannon</surname><given-names>P</given-names></name><name><surname>Collins</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>RB</given-names></name><name><surname>de Jong</surname><given-names>M</given-names></name><name><surname>Lambotte</surname><given-names>O</given-names></name><name><surname>Lamplough</surname><given-names>R</given-names></name><name><surname>Ndung’u</surname><given-names>T</given-names></name><name><surname>Sugarman</surname><given-names>J</given-names></name><name><surname>Tiemessen</surname><given-names>CT</given-names></name><name><surname>Vandekerckhove</surname><given-names>L</given-names></name><name><surname>Lewin</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Research priorities for an HIV cure: International AIDS society global scientific strategy 2021</article-title><source>Nature Medicine</source><volume>27</volume><fpage>2085</fpage><lpage>2098</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01590-5</pub-id><pub-id pub-id-type="pmid">34848888</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doering</surname><given-names>TA</given-names></name><name><surname>Crawford</surname><given-names>A</given-names></name><name><surname>Angelosanto</surname><given-names>JM</given-names></name><name><surname>Paley</surname><given-names>MA</given-names></name><name><surname>Ziegler</surname><given-names>CG</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory</article-title><source>Immunity</source><volume>37</volume><fpage>1130</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.08.021</pub-id><pub-id pub-id-type="pmid">23159438</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fromentin</surname><given-names>R</given-names></name><name><surname>DaFonseca</surname><given-names>S</given-names></name><name><surname>Costiniuk</surname><given-names>CT</given-names></name><name><surname>El-Far</surname><given-names>M</given-names></name><name><surname>Procopio</surname><given-names>FA</given-names></name><name><surname>Hecht</surname><given-names>FM</given-names></name><name><surname>Hoh</surname><given-names>R</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Hazuda</surname><given-names>DJ</given-names></name><name><surname>Lewin</surname><given-names>SR</given-names></name><name><surname>Routy</surname><given-names>J-P</given-names></name><name><surname>Sékaly</surname><given-names>R-P</given-names></name><name><surname>Chomont</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PD-1 blockade potentiates HIV latency reversal ex vivo in CD4<sup>+</sup> T cells from ART-suppressed individuals</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>814</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-08798-7</pub-id><pub-id pub-id-type="pmid">30778080</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaffen</surname><given-names>SL</given-names></name><name><surname>Liu</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Overview of interleukin-2 function, production and clinical applications</article-title><source>Cytokine</source><volume>28</volume><fpage>109</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2004.06.010</pub-id><pub-id pub-id-type="pmid">15473953</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gay</surname><given-names>CL</given-names></name><name><surname>Bosch</surname><given-names>RJ</given-names></name><name><surname>Ritz</surname><given-names>J</given-names></name><name><surname>Hataye</surname><given-names>JM</given-names></name><name><surname>Aga</surname><given-names>E</given-names></name><name><surname>Tressler</surname><given-names>RL</given-names></name><name><surname>Mason</surname><given-names>SW</given-names></name><name><surname>Hwang</surname><given-names>CK</given-names></name><name><surname>Grasela</surname><given-names>DM</given-names></name><name><surname>Ray</surname><given-names>N</given-names></name><name><surname>Cyktor</surname><given-names>JC</given-names></name><name><surname>Coffin</surname><given-names>JM</given-names></name><name><surname>Acosta</surname><given-names>EP</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name><name><surname>Mellors</surname><given-names>JW</given-names></name><name><surname>Eron</surname><given-names>JJ</given-names></name><collab>AIDS Clinical Trials 5326 Study Team</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Clinical trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy</article-title><source>The Journal of Infectious Diseases</source><volume>215</volume><fpage>1725</fpage><lpage>1733</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix191</pub-id><pub-id pub-id-type="pmid">28431010</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Cao</surname><given-names>M</given-names></name><name><surname>Morán</surname><given-names>T</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Garcia-Corbacho</surname><given-names>J</given-names></name><name><surname>Bracht</surname><given-names>JWP</given-names></name><name><surname>Bernabe</surname><given-names>R</given-names></name><name><surname>Juan</surname><given-names>O</given-names></name><name><surname>de Castro</surname><given-names>J</given-names></name><name><surname>Blanco</surname><given-names>R</given-names></name><name><surname>Drozdowskyj</surname><given-names>A</given-names></name><name><surname>Argilaguet</surname><given-names>J</given-names></name><name><surname>Meyerhans</surname><given-names>A</given-names></name><name><surname>Blanco</surname><given-names>J</given-names></name><name><surname>Prado</surname><given-names>JG</given-names></name><name><surname>Carrillo</surname><given-names>J</given-names></name><name><surname>Clotet</surname><given-names>B</given-names></name><name><surname>Massuti</surname><given-names>B</given-names></name><name><surname>Provencio</surname><given-names>M</given-names></name><name><surname>Molina-Vila</surname><given-names>MA</given-names></name><name><surname>Mayo de Las Casa</surname><given-names>C</given-names></name><name><surname>Garzon</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>C-Y</given-names></name><name><surname>Martinez-Picado</surname><given-names>J</given-names></name><name><surname>Rosell</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 Infection: the phase 2 durvast study</article-title><source>JAMA Oncology</source><volume>6</volume><fpage>1063</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2020.0465</pub-id><pub-id pub-id-type="pmid">32271353</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goulder</surname><given-names>PJR</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>HIV and HLA class I: an evolving relationship</article-title><source>Immunity</source><volume>37</volume><fpage>426</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.09.005</pub-id><pub-id pub-id-type="pmid">22999948</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graydon</surname><given-names>CG</given-names></name><name><surname>Balasko</surname><given-names>AL</given-names></name><name><surname>Fowke</surname><given-names>KR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Roles, function and relevance of LAG3 in HIV infection</article-title><source>PLOS Pathogens</source><volume>15</volume><elocation-id>e1007429</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007429</pub-id><pub-id pub-id-type="pmid">30653605</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guihot</surname><given-names>A</given-names></name><name><surname>Marcelin</surname><given-names>A-G</given-names></name><name><surname>Massiani</surname><given-names>M-A</given-names></name><name><surname>Samri</surname><given-names>A</given-names></name><name><surname>Soulié</surname><given-names>C</given-names></name><name><surname>Autran</surname><given-names>B</given-names></name><name><surname>Spano</surname><given-names>J-P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer</article-title><source>Annals of Oncology</source><volume>29</volume><fpage>517</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdx696</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>PK</given-names></name><name><surname>Godec</surname><given-names>J</given-names></name><name><surname>Wolski</surname><given-names>D</given-names></name><name><surname>Adland</surname><given-names>E</given-names></name><name><surname>Yates</surname><given-names>K</given-names></name><name><surname>Pauken</surname><given-names>KE</given-names></name><name><surname>Cosgrove</surname><given-names>C</given-names></name><name><surname>Ledderose</surname><given-names>C</given-names></name><name><surname>Junger</surname><given-names>WG</given-names></name><name><surname>Robson</surname><given-names>SC</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name><name><surname>Goulder</surname><given-names>PJR</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name><name><surname>Lauer</surname><given-names>GM</given-names></name><name><surname>Haining</surname><given-names>WN</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CD39 expression identifies terminally exhausted CD8+ T cells</article-title><source>PLOS Pathogens</source><volume>11</volume><elocation-id>e1005177</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005177</pub-id><pub-id pub-id-type="pmid">26485519</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harjunpää</surname><given-names>H</given-names></name><name><surname>Guillerey</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>TIGIT as an emerging immune checkpoint</article-title><source>Clinical and Experimental Immunology</source><volume>200</volume><fpage>108</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1111/cei.13407</pub-id><pub-id pub-id-type="pmid">31828774</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Pantazis</surname><given-names>N</given-names></name><name><surname>Martin</surname><given-names>GE</given-names></name><name><surname>Hickling</surname><given-names>S</given-names></name><name><surname>Hurst</surname><given-names>J</given-names></name><name><surname>Meyerowitz</surname><given-names>J</given-names></name><name><surname>Willberg</surname><given-names>CB</given-names></name><name><surname>Robinson</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>H</given-names></name><name><surname>Fisher</surname><given-names>M</given-names></name><name><surname>Kinloch</surname><given-names>S</given-names></name><name><surname>Babiker</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>J</given-names></name><name><surname>Nwokolo</surname><given-names>N</given-names></name><name><surname>Fox</surname><given-names>J</given-names></name><name><surname>Fidler</surname><given-names>S</given-names></name><name><surname>Phillips</surname><given-names>R</given-names></name><name><surname>Frater</surname><given-names>J</given-names></name><collab>SPARTAC and CHERUB Investigators</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection</article-title><source>PLOS Pathogens</source><volume>12</volume><elocation-id>e1005661</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005661</pub-id><pub-id pub-id-type="pmid">27415828</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Sheng</surname><given-names>Q</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Hua</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Exhausted CD8+T cells in the tumor immune microenvironment: new pathways to therapy</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>622509</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.622509</pub-id><pub-id pub-id-type="pmid">33633741</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joller</surname><given-names>N</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tim-3, Lag-3, and TIGIT</article-title><source>Current Topics in Microbiology and Immunology</source><volume>410</volume><fpage>127</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1007/82_2017_62</pub-id><pub-id pub-id-type="pmid">28900677</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>RB</given-names></name><name><surname>Ndhlovu</surname><given-names>LC</given-names></name><name><surname>Barbour</surname><given-names>JD</given-names></name><name><surname>Sheth</surname><given-names>PM</given-names></name><name><surname>Jha</surname><given-names>AR</given-names></name><name><surname>Long</surname><given-names>BR</given-names></name><name><surname>Wong</surname><given-names>JC</given-names></name><name><surname>Satkunarajah</surname><given-names>M</given-names></name><name><surname>Schweneker</surname><given-names>M</given-names></name><name><surname>Chapman</surname><given-names>JM</given-names></name><name><surname>Gyenes</surname><given-names>G</given-names></name><name><surname>Vali</surname><given-names>B</given-names></name><name><surname>Hyrcza</surname><given-names>MD</given-names></name><name><surname>Yue</surname><given-names>FY</given-names></name><name><surname>Kovacs</surname><given-names>C</given-names></name><name><surname>Sassi</surname><given-names>A</given-names></name><name><surname>Loutfy</surname><given-names>M</given-names></name><name><surname>Halpenny</surname><given-names>R</given-names></name><name><surname>Persad</surname><given-names>D</given-names></name><name><surname>Spotts</surname><given-names>G</given-names></name><name><surname>Hecht</surname><given-names>FM</given-names></name><name><surname>Chun</surname><given-names>T-W</given-names></name><name><surname>McCune</surname><given-names>JM</given-names></name><name><surname>Kaul</surname><given-names>R</given-names></name><name><surname>Rini</surname><given-names>JM</given-names></name><name><surname>Nixon</surname><given-names>DF</given-names></name><name><surname>Ostrowski</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection</article-title><source>The Journal of Experimental Medicine</source><volume>205</volume><fpage>2763</fpage><lpage>2779</lpage><pub-id pub-id-type="doi">10.1084/jem.20081398</pub-id><pub-id pub-id-type="pmid">19001139</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kløverpris</surname><given-names>HN</given-names></name><name><surname>Payne</surname><given-names>RP</given-names></name><name><surname>Sacha</surname><given-names>JB</given-names></name><name><surname>Rasaiyaah</surname><given-names>JT</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Takiguchi</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>OO</given-names></name><name><surname>Towers</surname><given-names>GJ</given-names></name><name><surname>Goulder</surname><given-names>P</given-names></name><name><surname>Prado</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Early antigen presentation of protective HIV-1 KF11Gag and KK10Gag epitopes from incoming viral particles facilitates rapid recognition of infected cells by specific CD8 <sup>+</sup> T cells</article-title><source>Journal of Virology</source><volume>87</volume><fpage>2628</fpage><lpage>2638</lpage><pub-id pub-id-type="doi">10.1128/JVI.02131-12</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kou</surname><given-names>ZC</given-names></name><name><surname>Halloran</surname><given-names>M</given-names></name><name><surname>Lee-Parritz</surname><given-names>D</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Simon</surname><given-names>M</given-names></name><name><surname>Sehgal</surname><given-names>PK</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>ZW</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>In vivo effects of a bacterial superantigen on macaque TCR repertoires</article-title><source>Journal of Immunology</source><volume>160</volume><fpage>5170</fpage><lpage>5180</lpage><pub-id pub-id-type="pmid">9590270</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Garff</surname><given-names>G</given-names></name><name><surname>Samri</surname><given-names>A</given-names></name><name><surname>Lambert-Niclot</surname><given-names>S</given-names></name><name><surname>Even</surname><given-names>S</given-names></name><name><surname>Lavolé</surname><given-names>A</given-names></name><name><surname>Cadranel</surname><given-names>J</given-names></name><name><surname>Spano</surname><given-names>J-P</given-names></name><name><surname>Autran</surname><given-names>B</given-names></name><name><surname>Marcelin</surname><given-names>A-G</given-names></name><name><surname>Guihot</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab</article-title><source>AIDS</source><volume>31</volume><fpage>1048</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001429</pub-id><pub-id pub-id-type="pmid">28350581</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruhashi</surname><given-names>T</given-names></name><name><surname>Sugiura</surname><given-names>D</given-names></name><name><surname>Okazaki</surname><given-names>IM</given-names></name><name><surname>Okazaki</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>LAG-3: from molecular functions to clinical applications</article-title><source>Journal for Immunotherapy of Cancer</source><volume>8</volume><elocation-id>e001014</elocation-id><pub-id pub-id-type="doi">10.1136/jitc-2020-001014</pub-id><pub-id pub-id-type="pmid">32929051</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBrien</surname><given-names>JB</given-names></name><name><surname>Kumar</surname><given-names>NA</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mechanisms of CD8<sup>+</sup> T cell-mediated suppression of HIV/SIV replication</article-title><source>European Journal of Immunology</source><volume>48</volume><fpage>898</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.1002/eji.201747172</pub-id><pub-id pub-id-type="pmid">29427516</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migueles</surname><given-names>SA</given-names></name><name><surname>Osborne</surname><given-names>CM</given-names></name><name><surname>Royce</surname><given-names>C</given-names></name><name><surname>Compton</surname><given-names>AA</given-names></name><name><surname>Joshi</surname><given-names>RP</given-names></name><name><surname>Weeks</surname><given-names>KA</given-names></name><name><surname>Rood</surname><given-names>JE</given-names></name><name><surname>Berkley</surname><given-names>AM</given-names></name><name><surname>Sacha</surname><given-names>JB</given-names></name><name><surname>Cogliano-Shutta</surname><given-names>NA</given-names></name><name><surname>Lloyd</surname><given-names>M</given-names></name><name><surname>Roby</surname><given-names>G</given-names></name><name><surname>Kwan</surname><given-names>R</given-names></name><name><surname>McLaughlin</surname><given-names>M</given-names></name><name><surname>Stallings</surname><given-names>S</given-names></name><name><surname>Rehm</surname><given-names>C</given-names></name><name><surname>O’Shea</surname><given-names>MA</given-names></name><name><surname>Mican</surname><given-names>J</given-names></name><name><surname>Packard</surname><given-names>BZ</given-names></name><name><surname>Komoriya</surname><given-names>A</given-names></name><name><surname>Palmer</surname><given-names>S</given-names></name><name><surname>Wiegand</surname><given-names>AP</given-names></name><name><surname>Maldarelli</surname><given-names>F</given-names></name><name><surname>Coffin</surname><given-names>JM</given-names></name><name><surname>Mellors</surname><given-names>JW</given-names></name><name><surname>Hallahan</surname><given-names>CW</given-names></name><name><surname>Follman</surname><given-names>DA</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control</article-title><source>Immunity</source><volume>29</volume><fpage>1009</fpage><lpage>1021</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.10.010</pub-id><pub-id pub-id-type="pmid">19062316</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>S</given-names></name><name><surname>Deleage</surname><given-names>C</given-names></name><name><surname>Darko</surname><given-names>S</given-names></name><name><surname>Ransier</surname><given-names>A</given-names></name><name><surname>Truong</surname><given-names>DP</given-names></name><name><surname>Agarwal</surname><given-names>D</given-names></name><name><surname>Japp</surname><given-names>AS</given-names></name><name><surname>Wu</surname><given-names>VH</given-names></name><name><surname>Kuri-Cervantes</surname><given-names>L</given-names></name><name><surname>Abdel-Mohsen</surname><given-names>M</given-names></name><name><surname>Del Rio Estrada</surname><given-names>PM</given-names></name><name><surname>Ablanedo-Terrazas</surname><given-names>Y</given-names></name><name><surname>Gostick</surname><given-names>E</given-names></name><name><surname>Hoxie</surname><given-names>JA</given-names></name><name><surname>Zhang</surname><given-names>NR</given-names></name><name><surname>Naji</surname><given-names>A</given-names></name><name><surname>Reyes-Terán</surname><given-names>G</given-names></name><name><surname>Estes</surname><given-names>JD</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Buggert</surname><given-names>M</given-names></name><name><surname>Betts</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Elite control of HIV is associated with distinct functional and transcriptional signatures in lymphoid tissue CD8<sup>+</sup> T cells</article-title><source>Science Translational Medicine</source><volume>11</volume><elocation-id>eaax4077</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aax4077</pub-id><pub-id pub-id-type="pmid">31852798</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noyan</surname><given-names>K</given-names></name><name><surname>Nguyen</surname><given-names>S</given-names></name><name><surname>Betts</surname><given-names>MR</given-names></name><name><surname>Sönnerborg</surname><given-names>A</given-names></name><name><surname>Buggert</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Human immunodeficiency virus type-1 elite controllers maintain low co-expression of inhibitory receptors on CD4+ T cells</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>19</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00019</pub-id><pub-id pub-id-type="pmid">29403500</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pende</surname><given-names>D</given-names></name><name><surname>Castriconi</surname><given-names>R</given-names></name><name><surname>Romagnani</surname><given-names>P</given-names></name><name><surname>Spaggiari</surname><given-names>GM</given-names></name><name><surname>Marcenaro</surname><given-names>S</given-names></name><name><surname>Dondero</surname><given-names>A</given-names></name><name><surname>Lazzeri</surname><given-names>E</given-names></name><name><surname>Lasagni</surname><given-names>L</given-names></name><name><surname>Martini</surname><given-names>S</given-names></name><name><surname>Rivera</surname><given-names>P</given-names></name><name><surname>Capobianco</surname><given-names>A</given-names></name><name><surname>Moretta</surname><given-names>L</given-names></name><name><surname>Moretta</surname><given-names>A</given-names></name><name><surname>Bottino</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction</article-title><source>Blood</source><volume>107</volume><fpage>2030</fpage><lpage>2036</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-07-2696</pub-id><pub-id pub-id-type="pmid">16304049</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perdomo-Celis</surname><given-names>F</given-names></name><name><surname>Taborda</surname><given-names>NA</given-names></name><name><surname>Rugeles</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>CD8<sup>+</sup> T-Cell response to HIV infection in the era of antiretroviral therapy</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>1896</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.01896</pub-id><pub-id pub-id-type="pmid">31447862</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perdomo-Celis</surname><given-names>F</given-names></name><name><surname>Velilla</surname><given-names>PA</given-names></name><name><surname>Taborda</surname><given-names>NA</given-names></name><name><surname>Rugeles</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>An altered cytotoxic program of CD8+ T-cells in HIV-infected patients despite HAART-induced viral suppression</article-title><source>PLOS ONE</source><volume>14</volume><elocation-id>e0210540</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0210540</pub-id><pub-id pub-id-type="pmid">30625227</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pino</surname><given-names>M</given-names></name><name><surname>Pereira Ribeiro</surname><given-names>S</given-names></name><name><surname>Pagliuzza</surname><given-names>A</given-names></name><name><surname>Ghneim</surname><given-names>K</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Ryan</surname><given-names>E</given-names></name><name><surname>Harper</surname><given-names>JL</given-names></name><name><surname>King</surname><given-names>CT</given-names></name><name><surname>Welbourn</surname><given-names>S</given-names></name><name><surname>Micci</surname><given-names>L</given-names></name><name><surname>Aldrete</surname><given-names>S</given-names></name><name><surname>Delman</surname><given-names>KA</given-names></name><name><surname>Stuart</surname><given-names>T</given-names></name><name><surname>Lowe</surname><given-names>M</given-names></name><name><surname>Brenchley</surname><given-names>JM</given-names></name><name><surname>Derdeyn</surname><given-names>CA</given-names></name><name><surname>Easley</surname><given-names>K</given-names></name><name><surname>Sekaly</surname><given-names>RP</given-names></name><name><surname>Chomont</surname><given-names>N</given-names></name><name><surname>Paiardini</surname><given-names>M</given-names></name><name><surname>Marconi</surname><given-names>VC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Increased homeostatic cytokines and stability of HIV-infected memory CD4 T-cells identify individuals with suboptimal CD4 T-cell recovery on-ART</article-title><source>PLOS Pathogens</source><volume>17</volume><elocation-id>e1009825</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1009825</pub-id><pub-id pub-id-type="pmid">34449812</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="software"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><year iso-8601-date="2008">2008</year><data-title>R: A language and environment for statistical computing</data-title><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roederer</surname><given-names>M</given-names></name><name><surname>Nozzi</surname><given-names>JL</given-names></name><name><surname>Nason</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>SPICE: exploration and analysis of post-cytometric complex multivariate datasets</article-title><source>Cytometry. Part A</source><volume>79</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1002/cyto.a.21015</pub-id><pub-id pub-id-type="pmid">21265010</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz</surname><given-names>A</given-names></name><name><surname>Blanch-Lombarte</surname><given-names>O</given-names></name><name><surname>Jimenez-Moyano</surname><given-names>E</given-names></name><name><surname>Ouchi</surname><given-names>D</given-names></name><name><surname>Mothe</surname><given-names>B</given-names></name><name><surname>Peña</surname><given-names>R</given-names></name><name><surname>Galvez</surname><given-names>C</given-names></name><name><surname>Genescà</surname><given-names>M</given-names></name><name><surname>Martinez-Picado</surname><given-names>J</given-names></name><name><surname>Goulder</surname><given-names>P</given-names></name><name><surname>Barnard</surname><given-names>R</given-names></name><name><surname>Howell</surname><given-names>B</given-names></name><name><surname>Clotet</surname><given-names>B</given-names></name><name><surname>Prado</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Antigen production after latency reversal and expression of inhibitory receptors in CD8+ T cells limit the killing of HIV-1 reactivated cells</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>3162</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.03162</pub-id><pub-id pub-id-type="pmid">30723480</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutishauser</surname><given-names>RL</given-names></name><name><surname>Hartogensis</surname><given-names>W</given-names></name><name><surname>Deguit</surname><given-names>CD</given-names></name><name><surname>Krone</surname><given-names>M</given-names></name><name><surname>Hoh</surname><given-names>R</given-names></name><name><surname>Hecht</surname><given-names>FM</given-names></name><name><surname>Pilcher</surname><given-names>CD</given-names></name><name><surname>Bacchetti</surname><given-names>P</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Hunt</surname><given-names>PW</given-names></name><name><surname>McCune</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Early and delayed antiretroviral therapy results in comparable reductions in CD8<sup>+</sup> T cell exhaustion marker expression</article-title><source>AIDS Research and Human Retroviruses</source><volume>33</volume><fpage>658</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1089/AID.2016.0324</pub-id><pub-id pub-id-type="pmid">28335609</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabatos-Peyton</surname><given-names>CA</given-names></name><name><surname>Nevin</surname><given-names>J</given-names></name><name><surname>Brock</surname><given-names>A</given-names></name><name><surname>Venable</surname><given-names>JD</given-names></name><name><surname>Tan</surname><given-names>DJ</given-names></name><name><surname>Kassam</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Taraszka</surname><given-names>J</given-names></name><name><surname>Wesemann</surname><given-names>L</given-names></name><name><surname>Pertel</surname><given-names>T</given-names></name><name><surname>Acharya</surname><given-names>N</given-names></name><name><surname>Klapholz</surname><given-names>M</given-names></name><name><surname>Etminan</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Y-H</given-names></name><name><surname>Blumberg</surname><given-names>RS</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name><name><surname>Anderson</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy</article-title><source>Oncoimmunology</source><volume>7</volume><elocation-id>e1385690</elocation-id><pub-id pub-id-type="doi">10.1080/2162402X.2017.1385690</pub-id><pub-id pub-id-type="pmid">29308307</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sáez-Cirión</surname><given-names>A</given-names></name><name><surname>Lacabaratz</surname><given-names>C</given-names></name><name><surname>Lambotte</surname><given-names>O</given-names></name><name><surname>Versmisse</surname><given-names>P</given-names></name><name><surname>Urrutia</surname><given-names>A</given-names></name><name><surname>Boufassa</surname><given-names>F</given-names></name><name><surname>Barré-Sinoussi</surname><given-names>F</given-names></name><name><surname>Delfraissy</surname><given-names>J-F</given-names></name><name><surname>Sinet</surname><given-names>M</given-names></name><name><surname>Pancino</surname><given-names>G</given-names></name><name><surname>Venet</surname><given-names>A</given-names></name><collab>Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group</collab></person-group><year iso-8601-date="2007">2007</year><article-title>HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype</article-title><source>PNAS</source><volume>104</volume><fpage>6776</fpage><lpage>6781</lpage><pub-id pub-id-type="doi">10.1073/pnas.0611244104</pub-id><pub-id pub-id-type="pmid">17428922</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakuishi</surname><given-names>K</given-names></name><name><surname>Apetoh</surname><given-names>L</given-names></name><name><surname>Sullivan</surname><given-names>JM</given-names></name><name><surname>Blazar</surname><given-names>BR</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name><name><surname>Anderson</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity</article-title><source>The Journal of Experimental Medicine</source><volume>207</volume><fpage>2187</fpage><lpage>2194</lpage><pub-id pub-id-type="doi">10.1084/jem.20100643</pub-id><pub-id pub-id-type="pmid">20819927</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schildberg</surname><given-names>FA</given-names></name><name><surname>Klein</surname><given-names>SR</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Coinhibitory pathways in the B7-CD28 Ligand-receptor family</article-title><source>Immunity</source><volume>44</volume><fpage>955</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.05.002</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekine</surname><given-names>T</given-names></name><name><surname>Perez-Potti</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>S</given-names></name><name><surname>Gorin</surname><given-names>J-B</given-names></name><name><surname>Wu</surname><given-names>VH</given-names></name><name><surname>Gostick</surname><given-names>E</given-names></name><name><surname>Llewellyn-Lacey</surname><given-names>S</given-names></name><name><surname>Hammer</surname><given-names>Q</given-names></name><name><surname>Falck-Jones</surname><given-names>S</given-names></name><name><surname>Vangeti</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Smed-Sörensen</surname><given-names>A</given-names></name><name><surname>Gaballa</surname><given-names>A</given-names></name><name><surname>Uhlin</surname><given-names>M</given-names></name><name><surname>Sandberg</surname><given-names>JK</given-names></name><name><surname>Brander</surname><given-names>C</given-names></name><name><surname>Nowak</surname><given-names>P</given-names></name><name><surname>Goepfert</surname><given-names>PA</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Betts</surname><given-names>MR</given-names></name><name><surname>Buggert</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>TOX is expressed by exhausted and polyfunctional human effector memory CD8<sup>+</sup> T cells</article-title><source>Science Immunology</source><volume>5</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1126/sciimmunol.aba7918</pub-id><pub-id pub-id-type="pmid">32620560</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>DR</given-names></name><name><surname>Kaminski</surname><given-names>J</given-names></name><name><surname>Barnitz</surname><given-names>RA</given-names></name><name><surname>Kurachi</surname><given-names>M</given-names></name><name><surname>Gerdemann</surname><given-names>U</given-names></name><name><surname>Yates</surname><given-names>KB</given-names></name><name><surname>Tsao</surname><given-names>H-W</given-names></name><name><surname>Godec</surname><given-names>J</given-names></name><name><surname>LaFleur</surname><given-names>MW</given-names></name><name><surname>Brown</surname><given-names>FD</given-names></name><name><surname>Tonnerre</surname><given-names>P</given-names></name><name><surname>Chung</surname><given-names>RT</given-names></name><name><surname>Tully</surname><given-names>DC</given-names></name><name><surname>Allen</surname><given-names>TM</given-names></name><name><surname>Frahm</surname><given-names>N</given-names></name><name><surname>Lauer</surname><given-names>GM</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name><name><surname>Yosef</surname><given-names>N</given-names></name><name><surname>Haining</surname><given-names>WN</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The epigenetic landscape of T cell exhaustion</article-title><source>Science</source><volume>354</volume><fpage>1165</fpage><lpage>1169</lpage><pub-id pub-id-type="doi">10.1126/science.aae0491</pub-id><pub-id pub-id-type="pmid">27789799</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serrano-Villar</surname><given-names>S</given-names></name><name><surname>Sainz</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>SA</given-names></name><name><surname>Hunt</surname><given-names>PW</given-names></name><name><surname>Sinclair</surname><given-names>E</given-names></name><name><surname>Shacklett</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>HIV-Infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered t cell subsets</article-title><source>PLOS Pathogens</source><volume>10</volume><elocation-id>e1004078</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004078</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevenson</surname><given-names>EM</given-names></name><name><surname>Ward</surname><given-names>AR</given-names></name><name><surname>Truong</surname><given-names>R</given-names></name><name><surname>Thomas</surname><given-names>AS</given-names></name><name><surname>Huang</surname><given-names>S-H</given-names></name><name><surname>Dilling</surname><given-names>TR</given-names></name><name><surname>Terry</surname><given-names>S</given-names></name><name><surname>Bui</surname><given-names>JK</given-names></name><name><surname>Mota</surname><given-names>TM</given-names></name><name><surname>Danesh</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>GQ</given-names></name><name><surname>Gramatica</surname><given-names>A</given-names></name><name><surname>Khadka</surname><given-names>P</given-names></name><name><surname>Alberto</surname><given-names>WDC</given-names></name><name><surname>Gandhi</surname><given-names>RT</given-names></name><name><surname>McMahon</surname><given-names>DK</given-names></name><name><surname>Lalama</surname><given-names>CM</given-names></name><name><surname>Bosch</surname><given-names>RJ</given-names></name><name><surname>Macatangay</surname><given-names>B</given-names></name><name><surname>Cyktor</surname><given-names>JC</given-names></name><name><surname>Eron</surname><given-names>JJ</given-names></name><name><surname>Mellors</surname><given-names>JW</given-names></name><name><surname>Jones</surname><given-names>RB</given-names></name><collab>AIDS Clinical Trials Group A5321 Team</collab></person-group><year iso-8601-date="2021">2021</year><article-title>HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy</article-title><source>JCI Insight</source><volume>6</volume><elocation-id>e142640</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.142640</pub-id><pub-id pub-id-type="pmid">33400687</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tauriainen</surname><given-names>J</given-names></name><name><surname>Scharf</surname><given-names>L</given-names></name><name><surname>Frederiksen</surname><given-names>J</given-names></name><name><surname>Naji</surname><given-names>A</given-names></name><name><surname>Ljunggren</surname><given-names>H-G</given-names></name><name><surname>Sönnerborg</surname><given-names>A</given-names></name><name><surname>Lund</surname><given-names>O</given-names></name><name><surname>Reyes-Terán</surname><given-names>G</given-names></name><name><surname>Hecht</surname><given-names>FM</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Betts</surname><given-names>MR</given-names></name><name><surname>Buggert</surname><given-names>M</given-names></name><name><surname>Karlsson</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Perturbed CD8<sup>+</sup> T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>40354</elocation-id><pub-id pub-id-type="doi">10.1038/srep40354</pub-id><pub-id pub-id-type="pmid">28084312</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavenier</surname><given-names>J</given-names></name><name><surname>Langkilde</surname><given-names>A</given-names></name><name><surname>Haupt</surname><given-names>TH</given-names></name><name><surname>Henriksen</surname><given-names>JH</given-names></name><name><surname>Jensen</surname><given-names>FK</given-names></name><name><surname>Petersen</surname><given-names>J</given-names></name><name><surname>Andersen</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Immunosenescence of the CD8(+) T cell compartment is associated with HIV-infection, but only weakly reflects age-related processes of adipose tissue, metabolism, and muscle in antiretroviral therapy-treated HIV-infected patients and controls</article-title><source>BMC Immunology</source><volume>16</volume><elocation-id>72</elocation-id><pub-id pub-id-type="doi">10.1186/s12865-015-0136-6</pub-id><pub-id pub-id-type="pmid">26611787</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teigler</surname><given-names>JE</given-names></name><name><surname>Zelinskyy</surname><given-names>G</given-names></name><name><surname>Eller</surname><given-names>MA</given-names></name><name><surname>Bolton</surname><given-names>DL</given-names></name><name><surname>Marovich</surname><given-names>M</given-names></name><name><surname>Gordon</surname><given-names>AD</given-names></name><name><surname>Alrubayyi</surname><given-names>A</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name><name><surname>Robb</surname><given-names>ML</given-names></name><name><surname>Martin</surname><given-names>JN</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Michael</surname><given-names>NL</given-names></name><name><surname>Dittmer</surname><given-names>U</given-names></name><name><surname>Streeck</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Differential inhibitory receptor expression on t cells delineates functional capacities in chronic viral infection</article-title><source>Journal of Virology</source><volume>91</volume><elocation-id>e01263-17</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.01263-17</pub-id><pub-id pub-id-type="pmid">28904197</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Qiu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects</article-title><source>Journal of Immunology</source><volume>194</volume><fpage>3873</fpage><lpage>3882</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1402176</pub-id><pub-id pub-id-type="pmid">25780040</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trautmann</surname><given-names>L</given-names></name><name><surname>Janbazian</surname><given-names>L</given-names></name><name><surname>Chomont</surname><given-names>N</given-names></name><name><surname>Said</surname><given-names>EA</given-names></name><name><surname>Gimmig</surname><given-names>S</given-names></name><name><surname>Bessette</surname><given-names>B</given-names></name><name><surname>Boulassel</surname><given-names>M-R</given-names></name><name><surname>Delwart</surname><given-names>E</given-names></name><name><surname>Sepulveda</surname><given-names>H</given-names></name><name><surname>Balderas</surname><given-names>RS</given-names></name><name><surname>Routy</surname><given-names>J-P</given-names></name><name><surname>Haddad</surname><given-names>EK</given-names></name><name><surname>Sekaly</surname><given-names>R-P</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction</article-title><source>Nature Medicine</source><volume>12</volume><fpage>1198</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1038/nm1482</pub-id><pub-id pub-id-type="pmid">16917489</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Twomey</surname><given-names>JD</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cancer immunotherapy update: FDA-Approved checkpoint inhibitors and companion diagnostics</article-title><source>The AAPS Journal</source><volume>23</volume><elocation-id>39</elocation-id><pub-id pub-id-type="doi">10.1208/s12248-021-00574-0</pub-id><pub-id pub-id-type="pmid">33677681</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uldrick</surname><given-names>TS</given-names></name><name><surname>Adams</surname><given-names>SV</given-names></name><name><surname>Fromentin</surname><given-names>R</given-names></name><name><surname>Roche</surname><given-names>M</given-names></name><name><surname>Fling</surname><given-names>SP</given-names></name><name><surname>Gonçalves</surname><given-names>PH</given-names></name><name><surname>Lurain</surname><given-names>K</given-names></name><name><surname>Ramaswami</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>C-CJ</given-names></name><name><surname>Gorelick</surname><given-names>RJ</given-names></name><name><surname>Welker</surname><given-names>JL</given-names></name><name><surname>O’Donoghue</surname><given-names>L</given-names></name><name><surname>Choudhary</surname><given-names>H</given-names></name><name><surname>Lifson</surname><given-names>JD</given-names></name><name><surname>Rasmussen</surname><given-names>TA</given-names></name><name><surname>Rhodes</surname><given-names>A</given-names></name><name><surname>Tumpach</surname><given-names>C</given-names></name><name><surname>Yarchoan</surname><given-names>R</given-names></name><name><surname>Maldarelli</surname><given-names>F</given-names></name><name><surname>Cheever</surname><given-names>MA</given-names></name><name><surname>Sékaly</surname><given-names>R</given-names></name><name><surname>Chomont</surname><given-names>N</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Lewin</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy</article-title><source>Science Translational Medicine</source><volume>14</volume><elocation-id>eabl3836</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abl3836</pub-id><pub-id pub-id-type="pmid">35080914</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaddepally</surname><given-names>RK</given-names></name><name><surname>Kharel</surname><given-names>P</given-names></name><name><surname>Pandey</surname><given-names>R</given-names></name><name><surname>Garje</surname><given-names>R</given-names></name><name><surname>Chandra</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Review of indications of FDA-Approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence</article-title><source>Cancers</source><volume>12</volume><elocation-id>738</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12030738</pub-id><pub-id pub-id-type="pmid">32245016</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Maaten</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Visualizing data using t-SNE</article-title><source>Journal of Machine Learning Research: JMLR</source><volume>219</volume><fpage>187</fpage><lpage>202</lpage></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voskoboinik</surname><given-names>I</given-names></name><name><surname>Whisstock</surname><given-names>JC</given-names></name><name><surname>Trapani</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Perforin and granzymes: function, dysfunction and human pathology</article-title><source>Nature Reviews. Immunology</source><volume>15</volume><fpage>388</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1038/nri3839</pub-id><pub-id pub-id-type="pmid">25998963</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>JA</given-names></name><name><surname>Clutton</surname><given-names>G</given-names></name><name><surname>Goonetilleke</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Harnessing CD8+ T cells under HIV antiretroviral therapy</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>291</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00291</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>World Medical Association</collab></person-group><year iso-8601-date="2013">2013</year><article-title>World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects</article-title><source>JAMA</source><volume>310</volume><fpage>2191</fpage><lpage>2194</lpage><pub-id pub-id-type="doi">10.1001/jama.2013.281053</pub-id><pub-id pub-id-type="pmid">24141714</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Casazza</surname><given-names>JP</given-names></name><name><surname>Ferrari</surname><given-names>G</given-names></name><name><surname>Nason</surname><given-names>M</given-names></name><name><surname>Chattopadhyay</surname><given-names>PK</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name><name><surname>Gostick</surname><given-names>E</given-names></name><name><surname>Katsikis</surname><given-names>PD</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Haubrich</surname><given-names>R</given-names></name><name><surname>Petrovas</surname><given-names>C</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection</article-title><source>Blood</source><volume>117</volume><fpage>4805</fpage><lpage>4815</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-11-317297</pub-id><pub-id pub-id-type="pmid">21398582</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83737.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kirchhoff</surname><given-names>Frank</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032000t02</institution-id><institution>Ulm University Medical Center</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.07.13.499924" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.07.13.499924"/></front-stub><body><p>This important study shows that the expression of some inhibitory receptors on CD8 T cells is increased in people living with HIV (PLWH) and remains elevated even after years of viral suppression by antiretroviral therapy. The authors further provide convincing evidence that inhibition of TGIT partially restores the ability of CD8 T cells to produce CD107a but not the other functions and is relevant for researchers and clinicians interested in viral infections, especially HIV/AIDS.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83737.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kirchhoff</surname><given-names>Frank</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032000t02</institution-id><institution>Ulm University Medical Center</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.07.13.499924">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.07.13.499924v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Single-cell CD8<sup>+</sup> dynamics uncover the reduction of CD107a TIGIT+ memory HIV-1-specific cells in PLWH over a decade of ART&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Murim Choi as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. Revise the statistical analyses and consider correction for multiple comparisons and verify the validity of the use of mixing paired and unpaired comparisons in the same plots.</p><p>2. More primary data need to be included to prove the reliable detection of specific markers, such as Lag-3, Tim3, and CD39 and the potential biological of subtle differences should be critically discussed. Levels of baseline IR expression on naïve cells should be shown where appropriate.</p><p>3. The rationale for the selection of clusters for tSNE analysis needs to be provided.</p><p>4. Concerns about the utilization of a super-antigen as activators without knowing the absolute numbers of potential responding cells (Figure 3) and the interpretation of results shown in Figures 4 and 5 (see reviewer 3, points 4 and 5) need to be addressed.</p><p>5. Results from two data points do not allow us to conclude that there are continuous increases. Information on the magnitude of the HIV-specific CD8 T cell responses in the different cohorts should be provided.</p><p>6. It needs to be explained why the author directly focused on the CM component of CD8 HIV-specific responses instead of first looking at total HIV-specific CD8 T cells?</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. Please put this work in context with reference 25. That study demonstrated very similar results with respect to CD8 T cell expression of TIGIT; however, the prior study did show enhancement of IFN-g responses when TIGIT was blocked (CD107a was not analyzed).</p><p>2. For figure 1A, I believe there were 48 total PLWH analyzed not 24 as is currently shown (24 in S1 and 24 in S2). Also, the female/male ratio should be separated for both S1 and S2.</p><p>3. For the data demonstrated in figures 2-4, were the comparisons statistically corrected for multiple comparisons?</p><p>4. Please explain the importance of looking at SEB-stimulated T cells.</p><p>5. Please explain why only the three functional parameters were analyzed (CD107a, IFN-g, and IL-2).</p><p>6. It is unclear from the text, the effect of ART on these functional parameters. It appears that patients on ART for prolonged periods (S2) have some restoration of their HIV-specific CD8 T cells with respect to polyfunctionality. Please clarify as this is an important aspect with respect to the studies done for figure 5.</p><p>7. It appears that most of the analysis in figures 2-4 was unsupervised with the exception of supervised data shown for the HIV-specific data; however, it is unclear as to what parameters were supervised.</p><p>8. The following statement in the discussion &quot;These data may support further investigations 309 on the potential use of TIGIT expression in CD8<sup>+</sup> T cells as a biomarker of immune activation through residual replication in PLWH on ART&quot; needs more justification. There are numerous publications showing that residual replication does not significantly occur and several demonstrate that continued immune activation is due to microbial translocation. The latter is supported by the current work whereby CD4 T cell counts correlate with TIGIT expression.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Statistics (all figures):</p><p>The statistical analyses should be revised, ideally with a statistician. Correction for multiple comparisons should be considered, and the validity of the use of mixing paired and unpaired comparisons in the same plots verified.</p><p>Figure 1: The levels of baseline expression of IRs on phenotypically naïve cells should be presented as well. While they are expected to be low, different cytokines can upregulate IRs on T cells in the absence of TCR signaling. Figure 1FandG: The authors focus on S2 in the text. They should consider also mentioning that they found significant negative correlations between CD4<sup>+</sup> T-cell counts and the frequency of CM CD8<sup>+</sup> T Cells expressing 2 and &gt;1 IRs in the S1 condition.</p><p>Figure 2: Lines 198 -200 and at other places in the manuscript. The authors mention a continuous increase of effector-like clusters (and elsewhere, of other changes). It is not possible to confirm that these changes are a continuous process with only two time points, this statement should be revised.</p><p>Figure 3: The interpretation of the SEB-responsive cells seems to be &quot;cellular clusters susceptible to TCR activation&quot;. However, SEB as a superantigen will stimulate only some Vbeta families. This should be clarified.</p><p>Figure 4: Some information should be given on the magnitude of the HIV-specific CD8 T cell responses in the different cohorts, and how this magnitude over time for S1 and S2 pairs. It is important, because it may change the interpretation of the shift in the relative proportions of the clusters observed (absolute attrition of some? Or the expansion of others?).</p><p>The authors directly focus on the CM component of these HIV-specific responses, it is unclear why and it would be important to look first at total HIV-specific CD8 T cells. If there is a shift in the memory differentiation pattern (e.g, in relative proportions of CM vs EM and TM over time), this may change the findings.</p><p>The authors stimulate with HIV-1 GAG to select for HIV-1 specific CD8<sup>+</sup> T cells. Have they also tested other antigens (Nef, Env, Pol) in a subset of patients? Would they expect the results to be similar?</p><p>Figure 5: The functional assays with TIGIT blockade are limited and do not include other markers of cytotoxic cells (perforin, granzyme B expression…). It is not clear how these subsets compare to the other CD8 clusters in terms of CD107 expression.</p><p>Does the short-term ICB result in any changes to cell viability?</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>1. Data for Lag-3, Tim3, and CD39 shown in supplementary figure 1A does not appear to demonstrate reliable detection. Additional data should be shown to demonstrate convincing detection of these markers. Importantly, such raw data also needs to be shown for each of the stimulation conditions, and in the context of the functional outputs.</p><p>2. For the data shown in Figures 2,3,4, it is unclear why the stated number of clusters was chosen for the tSNE analysis. Whether this leads to the detection of meaningless clusters is unclear. In addition, in some cases, populations are grouped together, yet some of these grouped clusters appear disparate.</p><p>3. Many many statistical comparisons are made, yet there is no discussion of correction for multiple comparisons.</p><p>4. The differences between many groups appear very subtle despite being statistically different (pending adjustment for multiple comparisons). The authors should consider carefully what may be biologically relevant in the discussion.</p><p>5. The data analysis in Figure 3 is fundamentally flawed because the authors used super antigen as a 'polyclonal' activator. This is a great T cell activator but has to be interpreted carefully because every donor has an inherently different 'maximal' response based on the proportion of T cells bearing the appropriate TCR-BV to respond to SEB. This means that directly comparing total responding cells between groups is not particularly informative. Furthermore, without knowing the absolute number of potential responding cells (which was not measured here), it is not appropriate to interpret functional deficiencies within the population. Also, it is not correct to conclude polyclonal activation using SEB, because the clonality measure requires TCR assessment – not performed here. Within any given SEB-responding memory subset it is formally possible that a monoclonal activation could occur.</p><p>6. In Figures 4 and 5, it is difficult to interpret the data without knowing the actual magnitude of the responses to HIV, and the number of responding events recovered in any given subset examined. Did the authors have a cutoff for a minimum number of events to consider a positive response- both overall, and also within the subset populations?</p><p>7. Figure 5, the use of tSNE analysis does not seem necessary when memory subsets are simply examined with or without blockade. Also, how the memory subsets were defined should be described.</p><p>Stylistic comments.</p><p>1. The use of 'single-cell analysis' in the title and abstract (as well as several times in the paper) seems somewhat inappropriate at times given the more broad use of this term when referring to single-cell genomic studies. This manuscript is simply a flow cytometry study, which by definition is a single cell, but rarely described as such.</p><p>2. There are numerous stylistic and grammatical errors that should be fixed after careful reading; additionally:</p><p>– Lines 101-103 and 105-106 basically say the same thing.</p><p>– Lines 65-66, and 230-231 are not sentences.</p><p>– Line 205. define ICB.</p><p>– Line 267. fix 'PBCM.'</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83737.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. Revise the statistical analyses and consider correction for multiple comparisons and verify the validity of the use of mixing paired and unpaired comparisons in the same plots.</p></disp-quote><p>According to the reviewers, we have revised the statistical analyses and included the correction for multiple comparisons, modifying the results across Figures and Supplemental Figures. Regarding the statistics, we changed Figures 2, 3, and 4 to have the intergroup and intragroup comparisons in separate graphs to clarify the information. In addition, we have included in the material and methods section and figure legends information regarding the statistical analyses and the correction for multiple comparisons (Holm’s method) performed when appropriate. Specific questions raised by the reviewers are included in the following sections.</p><disp-quote content-type="editor-comment"><p>2. More primary data need to be included to prove the reliable detection of specific markers, such as Lag-3, Tim3, and CD39 and the potential biological of subtle differences should be critically discussed. Levels of baseline IR expression on naïve cells should be shown where appropriate.</p></disp-quote><p>In agreement with the reviewers, we have provided primary data on reliable detection of LAG-3, TIM-3, and CD39 in Figure 1 —figure supplement 1, and data on baseline IR expression in naïve cells in Figure 1 and Figure 1 —figure supplement 2. Also, the potential biological implications of subtle and transient differences between IRs expression in CD8<sup>+</sup> have been now included in the Discussion section (page 13).</p><p>Regarding the reliable detection of LAG-3, TIM-3, and CD39 markers. These markers have lower frequencies and fluorochrome intensities than PD-1 and TIGIT, comprising &lt; 10% of total CD8<sup>+</sup> T cells and subsets. To support the reliable detection, we have now provided source data of flowcytometry intensities for each fluorochrome compared with the Fluorescent minus one (FMO) intensity included now in Figure 1 —figure supplement 1. As shown in the figure, we can observe reliable detection for all the IRs markers despite differences in the intensities between fluorochromes compared with FMOs.</p><p>Regarding the baseline expression of IRs in naïve CD8<sup>+</sup> T cells, we have now included data when appropriate, as suggested by reviewers. Information regarding the baseline expression of IR in naïve cells is now included in Figure 1 and Figure 1 —figure supplement 2. These data indicate very low or undetectable levels of baseline IR expression in naïve CD8<sup>+</sup> T cells and subsets for all the IRs studied (TIGIT, PD-1, LAG-3, TIM-3, and CD39). This information further supports the reliable detection of IRs expression in total and CD8<sup>+</sup> cellular subsets. Including the information on naïve CD8<sup>+</sup> T cells brought new information regarding the composition of naïve populations by permutation analyses and demonstrated an interesting the reduction of CD8<sup>+</sup> naïve cells expressing no IRs and the increase of naïve cells expressing one IR (Figure 1C).</p><disp-quote content-type="editor-comment"><p>3. The rationale for the selection of clusters for tSNE analysis needs to be provided.</p></disp-quote><p>In agreement with the reviewers, we now provided the rationale for cluster identification in the Material and Methods under the Unsupervised immunophenotype data analysis section (pages 20-21): “We discovered cell communities using the Phenograph clustering technique. It operates by computing the Jaccard coefficient between nearest neighbours, which was set to 30 in all executions, and then locating cell communities (or clusters) using the Louvain method. This creates a network indicating phenotypic similarities between cells. The netSNE maps included representations of the identified cell communities, and additionally, we built a heatmap with the clusters in the columns and the markers of interest in the rows to better comprehend the phenotypical interpretation of each cluster.”</p><disp-quote content-type="editor-comment"><p>4. Concerns about the utilization of a super-antigen as activators without knowing the absolute numbers of potential responding cells (Figure 3) and the interpretation of results shown in Figures 4 and 5 (see reviewer 3, points 4 and 5) need to be addressed.</p></disp-quote><p>We appreciate the reviewers' concerns about using superantigen Staphylococcal enterotoxin B (SEB) as an activator and the need for information about the absolute number of potential responding cells. Considering these comments, we have now included all the information required under de Results section. Unsupervised phenotypic characterisation of SEB-activated CD8<sup>+</sup> T cells in PLWH in ART. In this section, we now justified the use of SEB to obtain complementary information on T-cell activation in response to pathogens involved in the disease by stimulating TCR-VB clonotypes, and previous studies in HIV-1 support the use of SEB to evaluate the effect of ICB in the recovery of T cell function (31,49,50). In addition, we provided information on the supervised analyses regarding the total frequency of SEB-activated CD8<sup>+</sup> T cells presented in Figure 3 —figure supplement 1, revised the Results section accordingly, and included the lack of TCR sequencing as a limitation for data interpretation in the Discussion section.</p><disp-quote content-type="editor-comment"><p>5. Results from two data points do not allow us to conclude that there are continuous increases. Information on the magnitude of the HIV-specific CD8 T cell responses in the different cohorts should be provided.</p></disp-quote><p>We agree with the reviewers that the analyses of two time-points may not allow to conclude continuous increases. According with the comment, we have now rephrased the content of the manuscript when appropriate, including the title of the article, excluding the concept of dynamics. In agreement with the comment, we have now included all the information on the supervised analyses of the magnitude of total HIV-1-specific CD8 T cells in Figure 4 —figure supplement 1.</p><disp-quote content-type="editor-comment"><p>6. It needs to be explained why the author directly focused on the CM component of CD8 HIV-specific responses instead of first looking at total HIV-specific CD8 T cells?</p></disp-quote><p>According with the reviewers’ comments, we have now rephrased the Results section “Reduction of HIV-1-specific CD8<sup>+</sup> T-cell clusters sharing memory-like phenotypes, TIGIT expression and low CD107a” include the analyses of all memory subsets, now in Figure 4F. We now have also included the supervised analyses of total HIV-1-specific CD8<sup>+</sup> T cells (Figure 4 —figure supplement 1).</p><p>The focus on the memory compartment comes from identifying alterations of memory-like clusters by unsupervised analyses of HIV-1-specific CD8<sup>+</sup> T cells and detecting continuous and significant increases of TIGIT CM cells in PLWH on ART (Figure 1D). This information is now summarised in the manuscript as follows (page 10): “These findings in memory-like clusters, together with the initial ones, accounting for increases in the frequency of TIGIT<sup>+</sup> and TIGIT<sup>+</sup>TIM-3<sup>+</sup> in CM and EFF cells on ART, led us to postulate then as potential markers of HIV-1-specific CD8<sup>+</sup> T-cell dysfunction in PLWH on ART. Despite no significant changes observed in the total frequency of CD107a, IFNγ and IL-2 HIV-1-specific CD8<sup>+</sup> T-cell responses between groups (Figure 4 —figure supplement 1A-B, Figure 4 – source data 3). The analyses of TIGIT and TIGIT+TIM-3 HIV-1-specific memory subsets revealed decreases in the frequency of CD107a TIGIT HIV-1-specific CD8<sup>+</sup> T cells limited to the CM compartment (Figure 4F, Figure 4 – source data 4). No changes in IFNγ and IL-2 were observed. Furthermore, polyfunctional analysis of TIGIT HIV-1-specific CM CD8<sup>+</sup>s identified a decrease in monofunctional CD107a<sup>+</sup> as well as in bifunctional CD107a<sup>+</sup>IFNγ<sup>+</sup> and CD107<sup>+</sup>IL-2<sup>+</sup> cells overtime on ART (Figure 4G). Overall, these data support a reduction of HIV-1-specific CD8<sup>+</sup> T-cell clusters sharing memory-like phenotypes, TIGIT expression and low CD107a in PLWH on ART.”</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. Please put this work in context with reference 25. That study demonstrated very similar results with respect to CD8 T cell expression of TIGIT; however, the prior study did show enhancement of IFN-g responses when TIGIT was blocked (CD107a was not analyzed).</p></disp-quote><p>According to this comment, we have now put in context our work with reference 25 in the Discussion section as follows (page 15): “These data contrast with Chew et al., which observed the recovery of IFNγ production by TIGIT blockade. However, they also reported a reduction in CD107a expression in TIGIT+ CD8 T cells in response to aCD3/aCD28 activation, supporting a dysfunctional profile of TIGIT+ CD8<sup>+</sup> T cells. Differences between study groups accounting for time on ART, samples tested and interindividual variability of in vitro ICB experiments may account for some of the differences observed.”</p><disp-quote content-type="editor-comment"><p>2. For figure 1A, I believe there were 48 total PLWH analyzed not 24 as is currently shown (24 in S1 and 24 in S2). Also, the female/male ratio should be separated for both S1 and S2.</p></disp-quote><p>To clarify this point, we have accordingly revised Figure 1A, including subjects, samples, and female/male ratio, Supplementary Table 1 and the Study groups section in the manuscript. In brief, we analysed 48 PLWH, 24 in Early infection and 24 in ART. From those 24 in ART, we analysed 48 samples, 24 at the S1 and 24 at the S2 time points. The female/male ratio is the same for S1 and S2 samples as all samples come from the same 24 individuals selected in ART.</p><disp-quote content-type="editor-comment"><p>3. For the data demonstrated in figures 2-4, were the comparisons statistically corrected for multiple comparisons?</p></disp-quote><p>According to the reviewer, we have revised all the statistical analysis for the manuscript and corrected for multiple comparisons when appropriate using Holm's method. The information regarding the statistical method is included in the Materials and methods section under Statistics (page 20-21) and figure legends when appropriate.</p><disp-quote content-type="editor-comment"><p>4. Please explain the importance of looking at SEB-stimulated T cells.</p></disp-quote><p>Considering this comment, we have now included all the information required under de Results section, Unsupervised phenotypic characterisation of SEB-activated CD8<sup>+</sup> T cells in PLWH in ART (page 8). Briefly, the use of Staphylococcal enterotoxin B (SEB) allows to characterise T-cell responses (in magnitude and function) to superantigen stimulation providing a complementary read out of response to pathogens involved in disease to antigen-specific T-cell responses. SEB has been previously used to monitor antigen-independent TCR activation through the cross-link of MHC class II and TCR VB of the T cell lymphocytes (Kou et al. 1998) and in vitro effect of the ICB (Lewin et al. 2022, and Teigler et al. 2017). We acknowledge the limitations of this kind of analysis in terms of TCR response and the functional profile observed, but also the interest of SEB-activated CD8<sup>+</sup> T cells as complementary information to the antigenspecific responses to potentially detect functional defects.</p><disp-quote content-type="editor-comment"><p>5. Please explain why only the three functional parameters were analyzed (CD107a, IFN-g, and IL-2).</p></disp-quote><p>We prioritise the analyses of five IRs (TIGIT, PD-1, LAG-3, TIM-3 and CD39) and lineage markers (CD45RA, CCR7 and CD27) in our panel, adding relevant functional markers such as CD107a, IFNγ and IL-2 that provide general and complementary aspects of CD8<sup>+</sup> T-cell functionality. From the functional parameters, we selected CD107a because it is widely used to detect cytolytic activity in CD8<sup>+</sup> T cells as an early marker based on degranulation (Voskoboinik, et al. 2015, Aktas et al. 2009), we selected IFNγ because it is a classical moderator of cellmediated immunity with pro-inflammatory actions and enhances the antiviral effects of CD8<sup>+</sup> T cells (Bhat et al. 2017) and selected IL-2 because it plays a crucial role in the expansion of CD8<sup>+</sup> T cells, regulates proliferation and homeostasis, and long-term memory responses of T-cell responses (Gaffen and K. D. Liu 2004, Akdis et al. 2016). The relevant references to support using these three functional parameters have been included in the manuscript (references 51 to 55).</p><disp-quote content-type="editor-comment"><p>6. It is unclear from the text, the effect of ART on these functional parameters. It appears that patients on ART for prolonged periods (S2) have some restoration of their HIV-specific CD8 T cells with respect to polyfunctionality. Please clarify as this is an important aspect with respect to the studies done for figure 5.</p></disp-quote><p>According to the reviewer, we revised the functional data of HIV-1-specific CD8<sup>+</sup> T cell responses. We have clarified the information in the Results section, new Figure 4, and new Figure 4 —figure supplement 1. All the information required is under de Results section, Reduction of HIV-1-specific CD8<sup>+</sup> T-cell clusters sharing memory-like phenotypes, TIGIT expression and low CD107a (page 9). Briefly, Figure 4F included scatter plots showing median and interquartile ranges of CD107a, IFNγ, and IL-2 expression in TIGIT and TIGIT+TIM-3 HIV1-specific memory CD8<sup>+</sup> T cell subsets. This analysis revealed decreased CD107a expression limited to the CM compartment in TIGIT HIV-1-specific CD8<sup>+</sup> T cells. In addition, we have now included in Figure 4G the polyfunctional analyses of CD107a, IFNγ, and IL-2 expression for TIGIT HIV-1-specific CM cells. The new polyfunctional analysis identified monofunctional CD107a+ cells as the most common phenotype reduced in TIGIT HIV-1-specific CM cells, followed by bifunctional CD107a+IFNγ+ and CD107a+IL-2+ double-positive cells overtime on ART. These data do not support the restoration of polyfunctional responses over prolonged periods of ART (S2).</p><disp-quote content-type="editor-comment"><p>7. It appears that most of the analysis in figures 2-4 was unsupervised with the exception of supervised data shown for the HIV-specific data; however, it is unclear as to what parameters were supervised.</p></disp-quote><p>In agreement with the comment, we have now included whether we use supervised or unsupervised analyses in the text and figure legends for analyses corresponding to Figures 2-4. For SEB-activated CD8<sup>+</sup> T cells, we used unsupervised net-SNE analyses and supervised classical analyses (Figure 3 and Figure 3 —figure supplement 1, respectively). Similarly, for HIV-1 -specific CD8<sup>+</sup> T-cells, unsupervised net-SNE analyses and supervised classical analyses were combined across data sets (Figure 4 and Figure 4 —figure supplement 1, respectively).</p><disp-quote content-type="editor-comment"><p>8. The following statement in the discussion &quot;These data may support further investigations 309 on the potential use of TIGIT expression in CD8<sup>+</sup> T cells as a biomarker of immune activation through residual replication in PLWH on ART&quot; needs more justification. There are numerous publications showing that residual replication does not significantly occur and several demonstrate that continued immune activation is due to microbial translocation. The latter is supported by the current work whereby CD4 T cell counts correlate with TIGIT expression.</p></disp-quote><p>According to the reviewer's comment, we have modified the content of the corresponding paragraph to clarify our statement focused on the association between TIGIT expression, poor immune recovery and persistent immune activation. We have now rewritten the content in the discussion as follows (page 12): “These data support continuous expression of TIGIT despite ART in agreement with previous studies (24,25,30,57,59) and uncover novel associations between TIGIT expression in CD8<sup>+</sup> T cells and poorer immune status in PLWH on ART. Thus, these data indicate a specific contribution of TIGIT expression to persistent immune activation and poor CD4<sup>+</sup> recovery on ART.”</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Statistics (all figures):</p><p>The statistical analyses should be revised, ideally with a statistician. Correction for multiple comparisons should be considered, and the validity of the use of mixing paired and unpaired comparisons in the same plots verified.</p></disp-quote><p>According to the reviewer, we have revised all the statistical analysis to correct our findings for multiple comparisons when appropriate using Holm's method. The information regarding the statistical method is included in the statistics section of the Material and Methods and the figure legends when appropriate.</p><disp-quote content-type="editor-comment"><p>Figure 1: The levels of baseline expression of IRs on phenotypically naïve cells should be presented as well. While they are expected to be low, different cytokines can upregulate IRs on T cells in the absence of TCR signaling.</p></disp-quote><p>Data on baseline levels of IRs expression in naïve CD8<sup>+</sup> T cells have been included in Figure 1 B-C and Figure 1 —figure supplement 2 B-C. These data demonstrate very low basal levels of IR expression in naïve CD8<sup>+</sup> T cells across the IRs analysed (TIGIT, PD-1, LAG-3, TIM-3 and CD39). Including the information of basal IRs expression in naïve CD8<sup>+</sup> T cells supports a reliable detection of IRs and uncovered new information of IRs expression now included in the Results section under, Alterations in CD8<sup>+</sup> T-cell IRs frequencies and expression patterns in PLWH are not mitigated by ART (page 5).</p><disp-quote content-type="editor-comment"><p>Figure 1F and G: The authors focus on S2 in the text. They should consider also mentioning that they found significant negative correlations between CD4<sup>+</sup> T-cell counts and the frequency of CM CD8<sup>+</sup> T Cells expressing 2 and &gt;1 IRs in the S1 condition.</p></disp-quote><p>According to the reviewer, we have clarified this point in the Results section under, Alterations in CD8<sup>+</sup> T-cell IRs frequencies and expression patterns in PLWH are not mitigated by ART (page 6) as follows: “Focusing on S1 (Figure 1F), we found significant negative correlations between CD4<sup>+</sup> T-cell counts and frequencies of CM CD8<sup>+</sup> T cells expressing 2 (p=0.0054, r=0.64) and &gt; 1 IRs (p=0.0087, r=-0.61). Focusing on S2 (Figure 1G), we observed significant negative correlations between CD4<sup>+</sup> T-cell counts and the frequency of total CD8<sup>+</sup> T cells expressing TIGIT<sup>+</sup> (p=0.0157, r=-0.58), expressing 1 IRs (p=0.0386, r=-0.54) or &gt;1 IRs (p=0.0386, r=-0.51). At the level of CD8<sup>+</sup> T-cell subsets, the expression of 2 IRs in CM and &gt;1 IR in TM negatively correlated with CD4<sup>+</sup> T-cell counts (p=0.0072, r=-0.64; p=0.0346, r=-0.52, respectively) (Figure 1G)”.</p><disp-quote content-type="editor-comment"><p>Figure 2: Lines 198 -200 and at other places in the manuscript. The authors mention a continuous increase of effector-like clusters (and elsewhere, of other changes). It is not possible to confirm that these changes are a continuous process with only two time points, this statement should be revised.</p></disp-quote><p>In agreement with the comment, the statement has been revised across the manuscript. We agree with the reviewer that the analyses of two time points may not allow us to conclude a continuous increase of effector-like clusters. Accordingly, we have rephrased the manuscript when appropriate.</p><disp-quote content-type="editor-comment"><p>Figure 3: The interpretation of the SEB-responsive cells seems to be &quot;cellular clusters susceptible to TCR activation&quot;. However, SEB as a superantigen will stimulate only some Vbeta families. This should be clarified.</p></disp-quote><p>In agreement with the comment, we have clarified the information and removed the term TCR activation by SEB-activated CD8<sup>+</sup> T cells. We have included a paragraph under the Results section, Unsupervised phenotypic characterisation of SEB-activated CD8<sup>+</sup> T cells in PLWH in ART (page 8) as follows: “Then, we evaluate CD8<sup>+</sup> T-cell responses by bacterial superantigen activation with Staphylococcal enterotoxin B (SEB). Using SEB can provide complementary information on T-cell activation in response to pathogens involved in the disease by stimulating TCR-VB clonotypes (31,49,50).”</p><disp-quote content-type="editor-comment"><p>Figure 4: Some information should be given on the magnitude of the HIV-specific CD8 T cell responses in the different cohorts, and how this magnitude over time for S1 and S2 pairs. It is important, because it may change the interpretation of the shift in the relative proportions of the clusters observed (absolute attrition of some? Or the expansion of others?).</p><p>The authors directly focus on the CM component of these HIV-specific responses, it is unclear why and it would be important to look first at total HIV-specific CD8 T cells. If there is a shift in the memory differentiation pattern (e.g, in relative proportions of CM vs EM and TM over time), this may change the findings.</p></disp-quote><p>According to the reviewer, we have revised the information on total HIV-1-specific CD8<sup>+</sup> T-cell responses and evaluated the magnitude of the response base on CD107a, IFNγ and IL-2 expression between study groups (Figure 4 —figure supplement 1). No differences in total HIV1-specific responses were observed between groups and over time on ART (S1 vs S2). Based on the unsupervised analyses, we focused on the memory compartment and TIGIT and TIGIT+TIM3 HIV-1-specific CD8<sup>+</sup> T cells and found differences by classical supervised analysis on the CM compartment (Figure 4F). In addition, we characterise the TIGIT CM HIV-1-specific CD8<sup>+</sup> T cells in terms of CD107a expression and polyfunctional profile with IFNγ and IL-2 (Figure 4G). We have clarified the information in the Results section, new Figure 4, and new Figure 4 —figure supplement 1. All the information required is under de Results section, Reduction of HIV-1-specific CD8<sup>+</sup> T-cell clusters sharing memory-like phenotypes, TIGIT expression and low CD107a (page 9-10).</p><disp-quote content-type="editor-comment"><p>The authors stimulate with HIV-1 GAG to select for HIV-1 specific CD8<sup>+</sup> T cells. Have they also tested other antigens (Nef, Env, Pol) in a subset of patients? Would they expect the results to be similar?</p></disp-quote><p>We acknowledge the interest in testing additional antigens to select for HIV-1-specific CD8<sup>+</sup> T cells. We have not performed in this study stimulations with other antigens, including Nef, Env, and Pol, in a subset of patients. We acknowledge this point as study limitation and the potential interest of testing complementary antigens to select HIV-1-specific CD8<sup>+</sup> T cells against early (Nef) and late virally-expressed proteins (Gag, Env). Indeed, previous studies by our group (Kloverpis et al., 2013, Ruiz et al. 2019) support the differences in the early vs late antigen recognition of HIV-1 proteins in the efficacy and kinetics of killing infected cells by CD8<sup>+</sup> T cells. We have included this information in the Discussion section (page 15): “We acknowledge several study limitations; First, the sample size of study groups and the use of peripheral blood samples underestimate the potential contribution of TIGIT expression to Tex in lymphoid tissues. Second, the use of only Gag as stimuli for the characterization of HV-1-specific CD8<sup>+</sup> T cell responses in the absence of TCR sequencing. Using alternative HIV-1 antigens such as Nef, Env or Pol may provide additional information on the profile of CD8<sup>+</sup> T-cell functional responses against early and late-expressed viral proteins in PLWH on ART (68, 69).</p><disp-quote content-type="editor-comment"><p>Figure 5: The functional assays with TIGIT blockade are limited and do not include other markers of cytotoxic cells (perforin, granzyme B expression…). It is not clear how these subsets compare to the other CD8 clusters in terms of CD107 expression.</p><p>Does the short-term ICB result in any changes to cell viability?</p></disp-quote><p>We acknowledge the interest in testing additional markers, including perforin and granzyme B, for a more complete characterisation of the recovery of the cytotoxic potential of HIV-1-specific CD8<sup>+</sup> T cells. We have now acknowledged this point as a study limitation and included this information in the Discussion section (page 15): “Third, limited ICB experiments to CD107a, INFγ and IL-2 functional markers without complementary cytotoxic markers (perforin, granzyme B). Forth, complementary transcriptomic, epigenetic, and metabolic markers are needed for a complete description of Tex's immune signatures linked to TIGIT expression in HIV-1 specific CD8<sup>+</sup> T cells in PLWH on ART”.</p><p>Additionally, we have revised the information regarding changes in cell viability by short-term ICB. We have based our analysis on the frequency of total live lymphocytes using live/dead probe by flow cytometry and compared the viability of the PBMCs in the presence of HIV-1 (HIV-1 Gag peptide pool) and in the presence of HIV-1+ IgG isotypes alone or combined. A similar comparison was performed between PBMCs in the presence of HIV-1 and the presence of blockade antibodies aTIGIT and aTIM-3 alone or combined. We have performed paired analysis (Wilcoxon matched-pairs signed rank test) correcting for multiple comparisons (Holm´s method) between conditions. Our results indicated no changes in cellular viability by short-term ICB as represented in <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>:</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>Graphs represent paired comparisons of the frequency of live cells in PBMC samples in short-term ICB studies.</title><p>A. Graphs indicate the percentage of live cells in HIV-1 condition (Gag peptide pool) compared to HIV-1 + IgG2 isotype, HIV-1 + IgG1 isotype and HIV-1 + IgG2a+IgG1. B. Graphs indicate the % of live cells in HIV-1 compared to HIV-1 + aTIGIT, HIV-1 + aTIM-3 and HIV-1 + aTIGIT+ aTIM-3.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83737-sa2-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>1. Data for Lag-3, Tim3, and CD39 shown in supplementary figure 1A does not appear to demonstrate reliable detection. Additional data should be shown to demonstrate convincing detection of these markers. Importantly, such raw data also needs to be shown for each of the stimulation conditions, and in the context of the functional outputs.</p></disp-quote><p>In agreement with the reviewer, we have demonstrated reliable detection of IRs in two ways; we have added Figure 1 —figure supplement 1B, including the comparison for the staining of all markers (TIGIT, PD-1, LAG-3, TIM-3 and CD39) in CD8<sup>+</sup> T cells with the corresponding FMO in cryopreserved PBMCs. This information supports the reliable detection of all the markers data is similar for the SEB or HIV-1 condition. Also, including the information on basal IRs expression in naïve CD8<sup>+</sup> T cells in Figure 1 and Figure 1 —figure supplement 2, requested by the previous reviewer, provides further evidence of the reliable detection of these markers.</p><disp-quote content-type="editor-comment"><p>2. For the data shown in Figures 2,3,4, it is unclear why the stated number of clusters was chosen for the tSNE analysis. Whether this leads to the detection of meaningless clusters is unclear. In addition, in some cases, populations are grouped together, yet some of these grouped clusters appear disparate.</p></disp-quote><p>We have revised and clarified the information regarding the tSNE analyses and eliminated cluster aggrupation to avoid problems in the interpretation of data analysis and representation. We now provided the rationale for cluster identification in the Material and Methods under the Unsupervised immunophenotype data analysis section (pages 19-20): “We discovered cell communities using the Phenograph clustering technique. It operates by computing the Jaccard coefficient between nearest neighbours, which was set to 30 in all executions, and then locating cell communities (or clusters) using the Louvain method. This creates a network indicating phenotypic similarities between cells. The netSNE maps included representations of the identified cell communities, and additionally, we built a heatmap with the clusters in the columns and the markers of interest in the rows to better comprehend the phenotypical interpretation of each cluster.”</p><disp-quote content-type="editor-comment"><p>3. Many many statistical comparisons are made, yet there is no discussion of correction for multiple comparisons.</p></disp-quote><p>We have revised the statistical analyses and included the correction for multiple comparisons, modifying the results across Figures and Supplemental Figures. Regarding the statistics, we changed Figures 2, 3, and 4 to have the intergroup and intragroup comparisons in separate graphs to clarify the information and correct for multiple comparisons. We have included information in the material and methods section and Figure legends regarding the statistical analyses and the correction for multiple comparisons (Holm’s method) performed when appropriate.</p><disp-quote content-type="editor-comment"><p>4. The differences between many groups appear very subtle despite being statistically different (pending adjustment for multiple comparisons). The authors should consider carefully what may be biologically relevant in the discussion</p></disp-quote><p>After adjusting for multiple comparisons, we revised the manuscript's analyses, figures and corresponding text. Additionally, we have carefully revised the discussion pointing to the potential biological significance of our findings.</p><disp-quote content-type="editor-comment"><p>5. The data analysis in Figure 3 is fundamentally flawed because the authors used super antigen as a 'polyclonal' activator. This is a great T cell activator but has to be interpreted carefully because every donor has an inherently different 'maximal' response based on the proportion of T cells bearing the appropriate TCR-BV to respond to SEB. This means that directly comparing total responding cells between groups is not particularly informative. Furthermore, without knowing the absolute number of potential responding cells (which was not measured here), it is not appropriate to interpret functional deficiencies within the population. Also, it is not correct to conclude polyclonal activation using SEB, because the clonality measure requires TCR assessment – not performed here. Within any given SEB-responding memory subset it is formally possible that a monoclonal activation could occur.</p></disp-quote><p>We appreciate the reviewer concerns about using superantigen Staphylococcal enterotoxin B (SEB) as an activator and the need for information about the absolute number of potential responding cells. Considering these comments, we have now included all the information required under de Results section, Unsupervised phenotypic characterization of SEB-activated CD8<sup>+</sup> T cells in PLWH in ART and removed the concept of polyclonal activator from the manuscript. In this section, we now justified the use of SEB to obtain complementary information on T-cell activation in response to pathogens involved in the disease by stimulating TCR-VB clonotypes, and previous studies in HIV-1 support the use of SEB to evaluate the effect of ICB in the recovery of T cell function (31,49,50). In addition, we provided information on the supervised analyses regarding the total frequency of SEB-activated CD8<sup>+</sup> T cells presented in Figure 3 —figure supplement 1, and revised the Results section carefully according to the findings. Also, we included the lack of TCR assessment by sequencing as a limitation for data interpretation in the Discussion section.</p><disp-quote content-type="editor-comment"><p>6. In Figures 4 and 5, it is difficult to interpret the data without knowing the actual magnitude of the responses to HIV, and the number of responding events recovered in any given subset examined. Did the authors have a cutoff for a minimum number of events to consider a positive response- both overall, and also within the subset populations?</p></disp-quote><p>We appreciate the reviewer's concerns regarding Figures 4 and 5. For Figure 4, we have analysed the information on total HIV-1-specific CD8<sup>+</sup> T-cell responses and evaluated the magnitude of the response base on CD107a, IFN and IL-2 expression between study groups by supervised analyses (Figure 4 —figure supplement 1). Also, the information for the cut-off values and minimum numbers of events to consider a positive CD8<sup>+</sup> T cell functional response based on CD107a, IFN and IL-2 by flow cytometry analyses is now included in the Material and Methods section (page 19) as follows: “We performed two technical replicates for SEB-activated and HIV1-specific CD8<sup>+</sup> T-cell cytokine production. We considered the cytokine response positive after background subtraction (mean of two technical replicates) used as the cut-off value. For each independent sample, we recorded a median of 1,000 events and 50 events positive for cytokines for total and CD8<sup>+</sup> T cell subsets, respectively.”</p><disp-quote content-type="editor-comment"><p>7. Figure 5, the use of tSNE analysis does not seem necessary when memory subsets are simply examined with or without blockade. Also, how the memory subsets were defined should be described.</p></disp-quote><p>In agreement with the comment, we have now modified Figure 5 and include representative dot plots of the ICB experiments for the different conditions tested (basal, Isotypes, αTIGIT, αTIM3, and αTIGIT+αTIM-3 blockade) and functional markers monitored (CD107a, IFNγ and IL-2) (Figure 5A). Also, we included specific net-SNE projections to represent the extent of mAb blockade (Figure 5B).</p><p>The definition of memory subsets CD8<sup>+</sup> T cells and the gating strategy followed for flow cytometry analysis is included in Figure 1 —figure supplement 1 and the Materials and methods section.</p><disp-quote content-type="editor-comment"><p>Stylistic comments.</p><p>1. The use of 'single-cell analysis' in the title and abstract (as well as several times in the paper) seems somewhat inappropriate at times given the more broad use of this term when referring to single-cell genomic studies. This manuscript is simply a flow cytometry study, which by definition is a single cell, but rarely described as such.</p></disp-quote><p>According to the comment, we have rephrased the manuscript's content when appropriate, including the title and excluding the concept of single-cell analysis across the manuscript.</p><disp-quote content-type="editor-comment"><p>2. There are numerous stylistic and grammatical errors that should be fixed after careful reading; additionally:</p></disp-quote><p>According to the comment, we have revised the complete manuscript for stylistic and grammatical errors</p><disp-quote content-type="editor-comment"><p>– Lines 101-103 and 105-106 basically say the same thing.</p></disp-quote><p>Revised.</p><disp-quote content-type="editor-comment"><p>– Lines 65-66, and 230-231 are not sentences.</p></disp-quote><p>Revised.</p><disp-quote content-type="editor-comment"><p>– Line 205. define ICB.</p></disp-quote><p>Revised.</p><disp-quote content-type="editor-comment"><p>– Line 267. fix 'PBCM.'</p></disp-quote><p>Revised.</p></body></sub-article></article>